Поиск
Закладки
Озвучить текст Озвучить книгу
Изменить режим чтения
Изменить размер шрифта
Оглавление
Для озвучивания и цитирования книги перейдите в режим постраничного просмотра.
Юношеский артрит с системным началом

Список литературы

  1. Petty RE, Laxer RM, Lindsley CB, et al. Textbook of pediatric rheumatology. 8th ed. Philadelphia: Elsevier, Inc 2020.
  2. Petty RE, Southwood TR, Manners P, et al. International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol. 2004;31:390–2.
  3. Баранов АА, Алексеева ЕИ, editors. Ревматические болезни у детей. Москва: ПедиатрЪ 2016.
  4. Cimaz R. Systemic-onset juvenile idiopathic arthritis. Autoimmun Rev. 2016;15:931–4. doi: 10.1016/j.autrev.2016.07.004
  5. Janow G, Schanberg LE, Setoguchi S, et al. The Systemic Juvenile Idiopathic Arthritis Cohort of the Childhood Arthritis and Rheumatology Research Alliance Registry: 2010-2013. J Rheumatol. 2016;43:1755–62. doi: 10.3899/jrheum.150997
  6. Onel KB, Horton DB, Lovell DJ, et al. 2021 American College of Rheumatology Guideline for the Treatment of Juvenile Idiopathic Arthritis: Therapeutic Approaches for Oligoarthritis, Temporomandibular Joint Arthritis, and Systemic Juvenile Idiopathic Arthritis. Arthritis Rheumatol. 2022;74:553–69. doi: 10.1002/art.42037
  7. Баранов АА, Алексеева ЕИ, Бзарова ТМ, et al. Протокол ведения пациентов с ювенильным артритом. Вопросы Современной Педиатрии. 2013;12:37–56.
  8. Alexeeva EI. Juvenile idiopathic arthritis: clinical picture, diagnosis, treatment. Curr Pediatr. 2015;14:78–94. doi: 10.15690/vsp.v14i1.1266
  9. John RM, Kenney-Riley K. Care of the Child with a Possible Rheumatological Disorder. In: John RM, ed. Pediatric Diagnostic Labs for Primary Care: An Evidence-based Approach. Cham: Springer International Publishing 2022:461–86.
  10. Martini A. Systemic juvenile idiopathic arthritis. Autoimmun Rev. 2012;12:56–9. doi: 10.1016/j.autrev.2012.07.022
  11. Ghosh JB. Juvenile Idiopathic Arthritis-Its Rare Presentation. Indian J Pediatr. 2012;79:262–4. doi: 10.1007/s12098-011-0484-z
  12. Mondal R, Sarkar S, Ghoshal A, et al. Congestive Heart Failure: An Uncommon Presentation of Systemic Onset Juvenile Idiopathic Arthritis (SOJIA). Indian J Pediatr. 2013;80:67–9. doi: 10.1007/s12098-011-0636-1
  13. Belozerov KE, Isupova EA, Solomatina NM, et al. Initial Respiratory System Involvement in Juvenile Idiopathic Arthritis with Systemic Onset Is a Marker of Interstitial Lung Disease: The Results of Retrospective Cohort Study Analysis. J Clin Med. 2024;13:3843. doi: 10.3390/jcm13133843
  14. Marzan KAB, Shaham B. Early Juvenile Idiopathic Arthritis. Rheum Dis Clin N Am. 2012;38:355–72. doi: 10.1016/j.rdc.2012.04.006
  15. Kim YD, Job AV, Cho W. Differential Diagnosis of Juvenile Idiopathic Arthritis. J Rheum Dis. 2017;24:131. doi: 10.4078/jrd.2017.24.3.131
  16. Onel KB, Horton DB, Lovell DJ, et al. 2021 American College of Rheumatology Guideline for the Treatment of Juvenile Idiopathic Arthritis: Recommendations for Nonpharmacologic Therapies, Medication Monitoring, Immunizations, and Imaging. Arthritis Rheumatol. 2022;74:570–85. doi: 10.1002/art.42036
  17. Тепаев РФ. Синдром диссеминированного внутрисосудистого свертывания у детей. Диагностика и лечение. Педиатрическая Фармакология. 2010;7:27–31.
  18. De Vere-Tyndall A, Macauley D, Ansell BM. Disseminated intravascular coagulation complicating systemic juvenile chronic arthritis (“Still’s disease”). Clin Rheumatol. 1983;2:415–8. doi: 10.1007/BF02041564
  19. Oren H, Cingöz I, Duman M, et al. Disseminated intravascular coagulation in pediatric patients: clinical and laboratory features and prognostic factors influencing the survival. Pediatr Hematol Oncol. 2005;22:679–88. doi: 10.1080/08880010500278749
  20. Rajagopal R, Thachil J, Monagle P. Disseminated intravascular coagulation in paediatrics. Arch Dis Child. 2017;102:187–93. doi: 10.1136/archdischild-2016-311053
  21. Scott JP, Gerber P, Maryjowski MC, et al. Evidence for intravascular coagulation in systemic onset, but not polyarticular, juvenile rheumatoid arthritis. Arthritis Rheum. 1985;28:256–61. doi: 10.1002/art.1780280304
  22. Schapkaitz E, Sherman GG, Jacobson BF, et al. Paediatric anticoagulation guidelines. S Afr Med J. 2012;102:171. doi: 10.7196/SAMJ.5471
  23. Manco-Johnson MJ. How I treat venous thrombosis in children. Blood. 2006;107:21–9. doi: 10.1182/blood-2004-11-4211
  24. Tolbert J, Carpenter SL. Common Acquired Causes of Thrombosis in Children. Curr Probl Pediatr Adolesc Health Care. 2013;43:169–77. doi: 10.1016/j.cppeds.2013.05.005
  25. Геморрагические и тромботические заболевания и синдромы у детей и подростков: патогенез, клиника, диагностика, терапия и профилактика : монография / Б.И. Кузник, В.Г. Стуров, Н.Ю. Левшин [и др.]. – 2-е изд., перераб. и доп. – Новосибирск : Наука, 2018. – 524 с.
  26. Ameri A, Anderson CM, Smith JH, et al. Thromboembolic Complications in a Pediatric Patient Population: Treatment with Direct Oral Anticoagulants. Monitoring of Treatment Efficiency with D-Dimer Levels and Safety Profile By Thromboelastogram. Blood. 2021;138:4270–4270. doi: 10.1182/blood-2021-146948
  27. Sepúlveda M P, Salgado U A, Barriga G J, et al. Usefulness of the thromboelastogram in children: correlation with habitual coagulation tests. Rev Chil Pediatr. 2019;90:617–23. doi: 10.32641/rchped.v90i6.930
  28. Verma A, Hemlata. Thromboelastography as a novel viscoelastic method for hemostasis monitoring: Its methodology, applications, and constraints. Glob J Transfus Med. 2017;2:8. doi: 10.4103/GJTM.GJTM_4_17
  29. Yuan W-H, Liu H-C, Zeng L-K, et al. [Change of Thrombelastography in Children’s DIC and Analysis of Its Sensitivity and Specificity for Diagnosis of DIC]. Zhongguo Shi Yan Xue Ye Xue Za Zhi 2017;25:847–52. doi:10.7534/j.issn.1009-2137.2017.03.039.
  30. Голуб И. Е., Сорокина Л. В. Избранные вопросы по общей анестезиологии (методические рекомендации для клинических ординаторов, с правом переиздания). – 2005.
  31. Михельсон, В. А., В. А. Сидоров, and С. М. Степаненко. “Анестезия и интенсивная терапия в педиатрии.” М.:«Дель рус (2007).
  32. Nik A, Mirfeizi Z, Rezaieyazdi Z, et al. ABO and Rh blood groups in patients with Lupus and Rheumatoid Arthritis. Casp J Intern Med. 2021;12. doi: 10.22088/cjim.12.4.568
  33. Salem GI, Gamal NM, Talaat EA, et al. Clinical Impact of the ABO Blood Type in Patients with Rheumatic Diseases: Is there a Link to the ABO and Rhesus? Mediterr J Rheumatol. 2021;32:237. doi: 10.31138/mjr.32.3.237
  34. Breda, L., Nozzi, M., De Sanctis, S., & Chiarelli, F. (2010). Laboratory Tests in the Diagnosis and Follow-Up of Pediatric Rheumatic Diseases: An Update. Seminars in Arthritis and Rheumatism, 40(1), 53–72. doi:10.1016/j.semarthrit.2008.12.
  35. Shenoi S, Wallace CA. Diagnosis and Treatment of Systemic Juvenile Idiopathic Arthritis. J Pediatr. 2016;177:19–26. doi: 10.1016/j.jpeds.2016.06.056
  36. Cortis E, Insalaco A. Macrophage activation syndrome in juvenile idiopathic arthritis. Acta Paediatr. 2006;95:38–41. doi: 10.1111/j.1651-2227.2006.tb02414.x
  37. Ahn JG. Role of Biomarkers in Juvenile Idiopathic Arthritis. J Rheum Dis. 2020;27:233–40. doi: 10.4078/jrd.2020.27.4.233
  38. Ben-Chetrit E, Gattorno M, Gul A, et al. Consensus proposal for taxonomy and definition of the autoinflammatory diseases (AIDs): a Delphi study. Ann Rheum Dis. 2018;77:1558–65. doi: 10.1136/annrheumdis-2017-212515
  39. Hashkes PJ, Laxer RM, Simon A, editors. Textbook of Autoinflammation. Cham: Springer International Publishing 2019.
  40. Limper M, de Kruif MD, Duits AJ, et al. The diagnostic role of Procalcitonin and other biomarkers in discriminating infectious from non-infectious fever. J Infect. 2010;60:409–16. doi: 10.1016/j.jinf.2010.03.016
  41. Щербина АЮ. Первичные иммунодефициты -реалии XXI века. Вопросы Гематологиионкологии И Иммунопатологии В Педиатрии. 2016;15:8-9–9. https://www.hemoncim.com/jour/article/view/142 (accessed 14 April 2020)
  42. Quesada-Masachs E, Άlvarez De La Sierra D, Garcia Prat M, et al. AB0165 In Depth Immunophenotypic Analysis In Juvenile Idiopathic Arthritis (JIA): A Crossectional Study. Ann Rheum Dis. 2016;75:952.3-953. doi: 10.1136/annrheumdis-2016-eular.4823
  43. Аксенова ВА, Барышников ЛА, Клевно НИ, et al. Новые возможности скрининга и диагностики различных проявлений туберкулезной инфекции у детей и подростков в России. Вопросы Современной Педиатрии. 2011;10:16–22. https://vsp.spr-journal.ru/jour/article/view/638 (accessed 14 April 2020)
  44. Aksenova VA, Klevno NI, Kazakov AV, et al. Preventive Tuberculosis Services Reduces the Risk of Local Forms of Tuberculosis Development in Children on Immunosuppressive Therapy: Retrospective Cohort Study. Curr Pediatr. 2020;19:346–51. doi: 10.15690/vsp.v19i5.2210
  45. Calzada-Hernández J, Anton J, Martín De Carpi J, et al. Dual latent tuberculosis screening with tuberculin skin tests and QuantiFERON-TB assays before TNF-α inhibitor initiation in children in Spain. Eur J Pediatr. 2022;182:307–17. doi: 10.1007/s00431-022-04640-3
  46. Бармина НА, Барышникова ЛА, Шурыгин АА, et al. Скрининговое обследование детей и подростков III, IV и V групп здоровья с применением нового диагностического теста. Туберкулез И Болезни Легких. 2015;0:40–1.
  47. Soon GS, Laxer RM. Approach to recurrent fever in childhood. Can Fam Physician Med Fam Can. 2017;63:756–62.
  48. Selmi C, Gershwin ME. Diagnosis and classification of reactive arthritis. Autoimmun Rev. 2014;13:546–9. doi: 10.1016/j.autrev.2014.01.005
  49. Zeidler H, Hudson AP. Reactive Arthritis Update: Spotlight on New and Rare Infectious Agents Implicated as Pathogens. Curr Rheumatol Rep. 2021;23:53. doi: 10.1007/s11926-021-01018-6
  50. Dembek ZF, Mothershead JL, Owens AN, et al. Psittacosis: An Underappreciated and Often Undiagnosed Disease. Pathogens. 2023;12:1165. doi: 10.3390/pathogens12091165
  51. Singh A, Karrar S. The Role of Intracellular Organisms in the Pathogenesis of Inflammatory Arthritis. Int J Inflamm. 2014;2014:1–8. doi: 10.1155/2014/158793
  52. Bentaleb I, Abdelghani KB, Rostom S, et al. Reactive Arthritis: Update. Curr Clin Microbiol Rep. 2020;7:124–32. doi: 10.1007/s40588-020-00152-6
  53. Yang W-C, Huang Y-C, Tsai M-H, et al. Salmonella Septic Arthritis Involving Multiple Joints in a Girl with Acute Lymphoblastic Leukemia at Diagnosis. Pediatr Neonatol. 2009;50:33–5. doi: 10.1016/S1875-9572(09)60027-9
  54. Kanakoudi-Tsakalidou, G Pardalos, P F. Persistent or Severe Course of Reactive Arthritis Following Salmonella enteritidis Infection: A prospective study of 9 cases. Scand J Rheumatol. 1998;27:431–4. doi: 10.1080/030097498442253
  55. Kurniawan A, Sitorus IP, Loho T, et al. A rare case of septic arthritis of the knee caused by Salmonella typhi with preexisting typhoid fever in a healthy, immunocompetent child – A case report. Int J Surg Case Rep. 2021;78:76–80. doi: 10.1016/j.ijscr.2020.12.003
  56. Leino R, Mäkelä A-L, Tiilikainen A, et al. Yersinia Arthritis in Children. Scand J Rheumatol. 1980;9:245–9. doi: 10.3109/03009748009112357
  57. Hannu T. Reactive arthritis after an outbreak of Yersinia pseudotuberculosis serotype O:3 infection. Ann Rheum Dis. 2003;62:866–9. doi: 10.1136/ard.62.9.866
  58. Jezequel C, Prigent JY, Loiseau-Corvez MN, et al. [Reactive arthritis caused by Yersinia in children. Report of 4 cases]. Ann Pediatr (Paris). 1991;38:318–22.
  59. Naija O. et al. A new case of reactive arthritis following Yersinia pseudotuberculosis serotype IV //Journal of Pediatric Infectious Diseases. – 2010. – Т. 5. – №. 02. – С. 193-194.
  60. Taccetti G, Trapani S, Ermini M, et al. Reactive arthritis triggered by Yersinia enterocolitica: a review of 18 pediatric cases. Clin Exp Rheumatol. 1994;12:681–4.
  61. Williams G. F. et al. Post-Yersinia Arthritis //Western Journal of Medicine. – 1980. – Т. 132. – №. 6. – С. 535.
  62. Hannu T. Reactive arthritis attributable to Shigella infection: a clinical and epidemiological nationwide study. Ann Rheum Dis. 2005;64:594–8. doi: 10.1136/ard.2004.027524
  63. Mazumder RN, Salam MA, Ali M, et al. Reactive arthritis associated with Shigella dysenteriae type 1 infection. J Diarrhoeal Dis Res. 1997;15:21–4.
  64. Plesca DA, Luminos M, Spatariu L, et al. Postinfectious arthritis in pediatric practice. Maedica. 2013;8:164–9.
  65. Sood SK. Lyme Disease in Children. Infect Dis Clin North Am. 2015;29:281–94. doi: 10.1016/j.idc.2015.02.011
  66. Orczyk K, Świdrowska-Jaros J, Smolewska E. When a patient suspected with juvenile idiopathic arthritis turns out to be diagnosed with an infectious disease – a review of Lyme arthritis in children. Pediatr Rheumatol. 2017;15:35. doi: 10.1186/s12969-017-0166-0
  67. Steffen, Hirsch. Diagnostik der Lyme-Borreliose. Ther Umsch. 2005;62:737–44. doi: 10.1024/0040-5930.62.11.737
  68. Shi T, Huang L, Tian J. Prevalence of Epstein-Barr Viral DNA among children at a single hospital in Suzhou, China. J Pediatr (Rio J). 2022;98:142–6. doi: 10.1016/j.jped.2021.05.006
  69. Houen G, Trier NH. Epstein-Barr Virus and Systemic Autoimmune Diseases. Front Immunol. 2021;11:587380. doi: 10.3389/fimmu.2020.587380
  70. Engelmann I, Petzold DR, Kosinska A, et al. Rapid quantitative PCR assays for the simultaneous detection of herpes simplex virus, varicella zoster virus, cytomegalovirus, Epstein-Barr virus, and human herpesvirus 6 DNA in blood and other clinical specimens. J Med Virol. 2008;80:467–77. doi: 10.1002/jmv.21095
  71. Бзарова Т., Алексеева Е., Акулова С. Случай эпштейна-барр вирусной инфекции, протекавшей под маской системного варианта ювенильного ревматоидного артрита. Вопросы современной педиатрии. 2007;6(3):101-106.
  72. Kharitonova LA, Soboleva NG. The role of the infectious factor in juvenile rheumatoid arthritis in children. Ross Vestn Perinatol Pediatr Russ Bull Perinatol Pediatr. 2018;63:59–63. doi: 10.21508/1027-4065-2018-63-3-59-63
  73. Солдатова Е. Ю. и др. Распространенность герпесвирусной инфекции у больных с различными формами и вариантами ювенильного артрита //Лечащий врач. – 2017. – №. 6. – С. 31-31.
  74. Banko A, Cirkovic A, Jeremic I, et al. Uncovering the Role of Epstein–Barr Virus Infection Markers for Remission in Rheumatoid Arthritis. Biomedicines. 2023;11:2375. doi: 10.3390/biomedicines11092375
  75. for the Paediatric Rheumatology International Trials Organisation (PRINTO), Giancane G, Swart JF, et al. Opportunistic infections in immunosuppressed patients with juvenile idiopathic arthritis: analysis by the Pharmachild Safety Adjudication Committee. Arthritis Res Ther. 2020;22:71. doi: 10.1186/s13075-020-02167-2
  76. Petty RE, Laxer RM, Lindsley CB, et al. Textbook of pediatric rheumatology. 8th ed. Philadelphia: Elsevier, Inc 2020.
  77. Liu Z, Zhang P, Tang S, et al. Urine real-time polymerase chain reaction detection for children virus pneumonia with acute human cytomegalovirus infection. BMC Infect Dis. 2014;14:245. doi: 10.1186/1471-2334-14-245
  78. A. Ross S, Novak Z, Pati S, et al. Overview of the Diagnosis of Cytomegalovirus Infection. Infect Disord - Drug Targets. 2011;11:466–74. doi: 10.2174/187152611797636703
  79. Slots J, Slots H. Bacterial and viral pathogens in saliva: disease relationship and infectious risk. Periodontol 2000. 2011;55:48–69. doi: 10.1111/j.1600-0757.2010.00361.x
  80. Strick LB, Wald A. Diagnostics for Herpes Simplex Virus: Is PCR the New Gold Standard? Mol Diagn Ther. 2006;10:17–28. doi: 10.1007/BF03256439
  81. Vince A, Dusek D. Imunosupresija i virusne infekcije u reumatskim bolestima [Immunosupression and viral infections in rheumatic diseases]. Reumatizam. 2007;54(2):58-62. Croatian. PMID: 18351141.
  82. Eisenstein EM, Wolf DG. Cytomegalovirus infection in pediatric rheumatic diseases: a review. Pediatr Rheumatol. 2010;8:17. doi: 10.1186/1546-0096-8-17
  83. Hanson V, Kornreich HK, Drexler E, et al. Some Immunologic Considerations in Focal Scleroderma and Progressive Systemic Sclerosis in Children. Pediatr Res. 1974;8:806–9. doi: 10.1203/00006450-197409000-00006
  84. Looker KJ, Magaret AS, May MT, et al. Global and Regional Estimates of Prevalent and Incident Herpes Simplex Virus Type 1 Infections in 2012. PLOS ONE. 2015;10:e0140765. doi: 10.1371/journal.pone.0140765
  85. McQuillan G, Kruszon-Moran D, Flagg EW, et al. Prevalence of Herpes Simplex Virus Type 1 and Type 2 in Persons Aged 14-49: United States, 2015-2016. NCHS Data Brief. 2018;1–8.
  86. Xu F, Lee FK, Morrow RA, et al. Seroprevalence of Herpes Simplex Virus Type 1 in Children in the United States. J Pediatr. 2007;151:374–7. doi: 10.1016/j.jpeds.2007.04.065
  87. Levin MJ, Weinberg A, Schmid DS. Herpes Simplex Virus and Varicella-Zoster Virus. Microbiol Spectr. 2016;4:4.3.49. doi: 10.1128/microbiolspec.DMIH2-0017-2015
  88. McAuley JB. Toxoplasmosis in Children: Pediatr Infect Dis J. 2008;27:161–2. doi: 10.1097/INF.0b013e3181658abb
  89. Villard O, Cimon B, L’Ollivier C, et al. Serological diagnosis of Toxoplasma gondii infection. Diagn Microbiol Infect Dis. 2016;84:22–33. doi: 10.1016/j.diagmicrobio.2015.09.009
  90. Dong W, Zhong Q, Gu Y-L, et al. Is Toxoplasma gondii infection a concern in individuals with rheumatic diseases? Evidence from a case-control study based on serological diagnosis. Microb Pathog. 2023;182:106257. doi: 10.1016/j.micpath.2023.106257
  91. Cascio A., Colomba C. Childhood Mediterranean visceral leishmaniasis //Le Infezioni in Medicina. – 2003. – Т. 11. – №. 1. – С. 5-10.
  92. Moltó A, Mateo L, Lloveras N, et al. Visceral leishmaniasis and macrophagic activation syndrome in a patient with rheumatoid arthritis under treatment with adalimumab. Joint Bone Spine. 2010;77:271–3. doi: 10.1016/j.jbspin.2010.01.011
  93. Kurizky PS, Marianelli FF, Cesetti MV, et al. A comprehensive systematic review of leishmaniasis in patients undergoing drug-induced immunosuppression for the treatment of dermatological, rheumatological and gastroenterological diseases. Rev Inst Med Trop São Paulo. 2020;62:e28. doi: 10.1590/s1678-9946202062028
  94. Indolfi G, Easterbrook P, Dusheiko G, et al. Hepatitis B virus infection in children and adolescents. Lancet Gastroenterol Hepatol. 2019;4:466–76. doi: 10.1016/S2468-1253(19)30042-1
  95. Mack CL, Adams D, Assis DN, et al. Diagnosis and Management of Autoimmune Hepatitis in Adults and Children: 2019 Practice Guidance and Guidelines From the American Association for the Study of Liver Diseases. Hepatology. 2020;72:671–722. doi: 10.1002/hep.31065
  96. Lampertico P, Agarwal K, Berg T, et al. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol. 2017;67:370–98. doi: 10.1016/j.jhep.2017.03.021
  97. Reust CE. Evaluation of primary immunodeficiency disease in children. Am Fam Physician. 2013;87:773–8.
  98. Key recommendations. WHO Recommendations on the Diagnosis of HIV Infection in Infants and Children. World Health Organization 2010.
  99. Robinson JL, Lee BE, Kothapalli S, et al. Use of Throat Swab or Saliva Specimens for Detection of Respiratory Viruses in Children. Clin Infect Dis. 2008;46:e61–4. doi: 10.1086/529386
  100. Hurd A, Beukelman T. Infectious Complications in Juvenile Idiopathic Arthritis. Curr Rheumatol Rep. 2013;15:327. doi: 10.1007/s11926-013-0327-1
  101. Chien Y-L, Huang F-L, Huang C-M, et al. Clinical approach to fever of unknown origin in children. J Microbiol Immunol Infect. 2017;50:893–8. doi: 10.1016/j.jmii.2015.08.007
  102. Ahmadinejad Z, Mansori S, Ziaee V, et al. Periodic Fever: a review on clinical, management and guideline for Iranian patients - part I. Iran J Pediatr 2014;24:1–13.
  103. Weiss SL, Peters MJ, Alhazzani W, et al. Surviving sepsis campaign international guidelines for the management of septic shock and sepsis-associated organ dysfunction in children. Intensive Care Med. 2020;46:10–67. doi: 10.1007/s00134-019-05878-6
  104. Howell MD, Davis AM. Management of Sepsis and Septic Shock. 2017;2.
  105. Ören H, Cingöz I, Duman M, et al. Disseminated intravascular coagulation in pediatric patients: Clinical and Laboratory Features and Prognostic Factors Influencing the Survival. Pediatr Hematol Oncol. 2005;22:679–88. doi: 10.1080/08880010500278749
  106. Foster BJ, Duffy CM, Sharma AK. Systemic juvenile rheumatoid arthritis complicated by two different renal lesions. Pediatr Nephrol. 1998;12:113–6. doi: 10.1007/s004670050416
  107. Del Giudice E, Marcellino A, Hoxha S, et al. Proteinuria and hematuria as early signs of renal involvement in juvenile idiopathic arthritis. Front Pediatr. 2024;12:1395961. doi: 10.3389/fped.2024.1395961
  108. Ruemmele FM, Veres G, Kolho KL, et al. Consensus guidelines of ECCO/ESPGHAN on the medical management of pediatric Crohn’s disease. J Crohns Colitis. 2014;8:1179–207. doi: 10.1016/j.crohns.2014.04.005
  109. Turner D, Ruemmele FM, Orlanski-Meyer E, et al. Management of Paediatric Ulcerative Colitis, Part 1: Ambulatory Care—An Evidence-based Guideline From European Crohn’s and Colitis Organization and European Society of Paediatric Gastroenterology, Hepatology and Nutrition. J Pediatr Gastroenterol Nutr. 2018;67:257–91. doi: 10.1097/MPG.0000000000002035
  110. Ferrara G, Pastore S, Sancin L, et al. Fecal Calprotectin to Detect Inflammatory Bowel Disease in Juvenile Idiopathic Arthritis. J Rheumatol. 2018;45:1418–21. doi: 10.3899/jrheum.171200
  111. Koca B, Sahin S, Adrovic A, et al. Cardiac involvement in juvenile idiopathic arthritis. Rheumatol Int. 2017;37:137–42. doi: 10.1007/s00296-016-3534-z
  112. Binstadt BA, Levine JC, Nigrovic PA, et al. Coronary Artery Dilation Among Patients Presenting With Systemic-Onset Juvenile Idiopathic Arthritis. Pediatrics. 2005;116:e89–93. doi: 10.1542/peds.2004-2190
  113. Boylan M. Should ultrasound be used routinely in the diagnosis of rheumatoid arthritis? Ir J Med Sci 1971 -. 2020;189:735–48. doi: 10.1007/s11845-019-02096-3
  114. Okamoto N, Yokota S, Takei S, et al. Clinical practice guidance for juvenile idiopathic arthritis (JIA) 2018. Mod Rheumatol. 2019;29:41–59. doi: 10.1080/14397595.2018.1514724
  115. Basra HAS, Humphries PD. Juvenile idiopathic arthritis: what is the utility of ultrasound? Br J Radiol. 2017;90:20160920. doi: 10.1259/bjr.20160920
  116. Chauvin NA, Doria AS. Ultrasound imaging of synovial inflammation in juvenile idiopathic arthritis. Pediatr Radiol. 2017;47:1160–70. doi: 10.1007/s00247-017-3934-6
  117. Malattia C, Rinaldi M, Martini A. The role of imaging in juvenile idiopathic arthritis. Expert Rev Clin Immunol. 2018;14:681–94. doi: 10.1080/1744666X.2018.1496019
  118. Balassy C, Miller SF. CT in children’s bones and joints: When, how and common findings. Eur J Radiol. 2013;82:1126–34. doi: 10.1016/j.ejrad.2011.12.007
  119. Munir S, Patil K, Miller E, et al. Juvenile Idiopathic Arthritis of the Axial Joints: A Systematic Review of the Diagnostic Accuracy and Predictive Value of Conventional MRI. Am J Roentgenol. 2014;202:199–210. doi: 10.2214/AJR.12.10475
  120. García-Basteiro AL, DiNardo A, Saavedra B, et al. Point of care diagnostics for tuberculosis. Pulmonology. 2018;24:73–85. doi: 10.1016/j.rppnen.2017.12.002
  121. Allen-Rhoades W, Whittle SB, Rainusso N. Pediatric Solid Tumors in Children and Adolescents: An Overview. Pediatr Rev. 2018;39:444–53. doi: 10.1542/pir.2017-0268
  122. Zucker EJ, Lee EY, Restrepo R, et al. Hip Disorders in Children. Am J Roentgenol. 2013;201:W776–96. doi: 10.2214/AJR.13.10623
  123. Jones NL, Koletzko S, Goodman K, et al. Joint ESPGHAN/NASPGHAN Guidelines for the Management of Helicobacter pylori in Children and Adolescents (Update 2016). J Pediatr Gastroenterol Nutr. 2017;64:991–1003. doi: 10.1097/MPG.0000000000001594
  124. Kotilea K, Cadranel S, Salame A, et al. Efficacy and safety of bismuth‐based quadruple therapy for Helicobacter pylori eradication in children. Helicobacter. 2021;26:e12825. doi: 10.1111/hel.12825
  125. Sierra D, Wood M, Kolli S, et al. Pediatric Gastritis, Gastropathy, and Peptic Ulcer Disease. Pediatr Rev. 2018;39:542–9. doi: 10.1542/pir.2017-0234
  126. Бельмер С.В., Корниенко Е.А., Волынец Г.В., Гурова М.М., Звягин А.А., Камалова А.А., Луппова Н.Е., Нижевич А.А., Новикова В.П., Печкуров Д.В., Приворотский В.Ф., Сатаев В.У., Тяжева А.А., Файзуллина Р.А., Хавкин А.И. Диагностика и лечение хеликобактерной инфекции у детей. Экспериментальная и клиническая гастроэнтерология. 2021;(9):119-127. https://doi.org/10.31146/1682-8658-ecg-193-9-119-127..
  127. Бзарова Т.М., Щербаков П.Л., Алексеева Е.И., Чистякова Е.Г., and Валиева С.И.. “Лечение гастроэзофагеальной рефлюксной болезни у детей с юношеским артритом” Вопросы современной педиатрии, vol. 6, no. 4, 2007, pp. 17-22.
  128. Pichler J, Ong C, Shah N, et al. Histopathological features of gastrointestinal mucosal biopsies in children with juvenile idiopathic arthritis. Pediatr Res. 2016;79:895–901. doi: 10.1038/pr.2016.27
  129. Ashorn M, Verronen P, Ruuska T, et al. Upper endoscopic findings in children with active juvenile chronic arthritis. Acta Paediatr. 2003;92:558–61. doi: 10.1111/j.1651-2227.2003.tb02506.x
  130. Len C, Hilario MO, Kawakami E, et al. Gastroduodenal lesions in children with juvenile rheumatoid arthritis. Hepatogastroenterology. 1999;46:991–6.
  131. Weber P, Brune T, Ganser G, et al. Gastrointestinal symptoms and permeability in patients with juvenile idiopathic arthritis. Clin Exp Rheumatol. 2003;21:657–62.
  132. Листопадова А. П. и др. Этиологическая структура хронического гастрита у детей, больных ювенильным хроническим артритом //Актуальные проблемы медицины. – 2014. – Т. 28. – №. 24 (195). – С. 33-36.
  133. Жолобова Е. С. и др. Воспалительные заболевания кишечника у пациентов с системным ювенильным артритом //Consilium Medicum. – 2023. – Т. 25. – №. 8. – С. 529-533.
  134. Maller J, Fox E, Park KT, et al. Inflammatory Bowel Disease in Children With Systemic Juvenile Idiopathic Arthritis. J Rheumatol. 2021;48:567–74. doi: 10.3899/jrheum.200230
  135. Broekaert IJ, Klein A, Windschall D, et al. Development of Inflammatory Bowel Disease in Children With Juvenile Idiopathic Arthritis Treated With Biologics. J Pediatr Gastroenterol Nutr. 2023;76:174–82. doi: 10.1097/MPG.0000000000003656
  136. Passo MH, Fitzgerald JF, Brandt KD. Arthritis associated with inflammatory bowel disease in children: Relationship of joint disease to activity and severity of bowel lesion. Dig Dis Sci. 1986;31:492–7. doi: 10.1007/BF01320313
  137. Biswas S. et al. IBD-Associated Arthritis Misdiagnosed as Juvenile Idiopathic Arthritis: A Case Report and Literature Review: 2091 //Official journal of the American College of Gastroenterology| ACG. – 2018. – Т. 113. – С. S1188-S1189.
  138. Martín Pedraz L, Galindo Zavala R, Blasco Alonso J, et al. Crohn’s disease in a patient with systemic onset juvenile idiopathic arthritis. Association or associated side effect of treatment? Reumatol Clínica Engl Ed. 2022;18:557–9. doi: 10.1016/j.reumae.2021.06.004
  139. De Cock D, Hyrich K. Malignancy and rheumatoid arthritis: Epidemiology, risk factors and management. Best Pract Res Clin Rheumatol. 2018;32:869–86. doi: 10.1016/j.berh.2019.03.011
  140. Lobo L, Antunes D. Chest CT in infants and children. Eur J Radiol. 2013;82:1108–17. doi: 10.1016/j.ejrad.2011.12.006
  141. Quezada A, Ramos S, Garcia M, et al. Lung involvement in rheumatologic diseases in children. Allergol Immunopathol (Madr). 2012;40:88–91. doi: 10.1016/j.aller.2011.02.009
  142. Brix N, Rosthøj S, Glerup M, et al. Identifying acute lymphoblastic leukemia mimicking juvenile idiopathic arthritis in children. PLOS ONE. 2020;15:e0237530. doi: 10.1371/journal.pone.0237530
  143. Allen-Rhoades W, Whittle SB, Rainusso N. Pediatric Solid Tumors in Children and Adolescents: An Overview. Pediatr Rev. 2018;39:444–53. doi: 10.1542/pir.2017-0268
  144. Nikishina I, Kolkhidova Z, Blank L, et al. AB1260 Significance of whole-body MRI in children with rheumatic diseases. Ann Rheum Dis. 2022;81:1739.3-1740. doi: 10.1136/annrheumdis-2022-eular.4671
  145. Eutsler EP, Khanna G. Whole-body magnetic resonance imaging in children: technique and clinical applications. Pediatr Radiol. 2016;46:858–72. doi: 10.1007/s00247-016-3586-y
  146. Ćwikła JB. New imaging techniques in reumathology: MRI, scintigraphy and PET. Pol J Radiol. 2013;78:48–56. doi: 10.12659/PJR.889138
  147. Fonseca MB, Gomes FHR, Valera ET, et al. Signs and symptoms of rheumatic diseases as first manifestation of pediatric cancer: diagnosis and prognosis implications. Rev Bras Reumatol Engl Ed. 2017;57:330–7. doi: 10.1016/j.rbre.2017.01.007
  148. Alias A, Rodriguez EJ, Bateman HE, et al. Rheumatology and oncology: an updated review of rheumatic manifestations of malignancy and anti-neoplastictherapy. Bull NYU Hosp Jt Dis. 2012;70:109–14.
  149. Loctin A, Bailly F, Laroche D, et al. Clinical interest of bone marrow aspiration in rheumatology: a practice-based observational study of 257 bone marrow aspirations. Clin Rheumatol. 2013;32:115–21. doi: 10.1007/s10067-012-2097-y
  150. Grebenyuk V. et al. Fever of unknown origin: case reports from routine clinical practice and a review //Klinicka Mikrobiologie a Infekcni Lekarstvi. – 2021. – Т. 27. – №. 4. – С. 148-157.
  151. Захарова И.Н., Османов И.М., Творогова Т.М., Горяйнова А.Н., Дмитриева Ю.А., Воробьева А.С., Короид Н.В. Длительная лихорадка у ребенка: в чем причина, как обследовать, лечить или не лечить? Медицинский совет. 2020;(10):151–162. doi: 10.21518/2079-701X-2020-10-151-162.
  152. Trapani S, Grisolia F, Simonini G, et al. Incidence of occult cancer in children presenting with musculoskeletal symptoms: a 10-year survey in a pediatric rheumatology unit. Semin Arthritis Rheum. 2000;29:348–59. doi: 10.1053/sarh.2000.5752
  153. Colamussi P, Prandini N, Cittanti C, et al. Scintigraphy in rheumatic diseases. Best Pract Res Clin Rheumatol. 2004;18:909–26. doi: 10.1016/j.berh.2004.07.003
  154. Zucker EJ, Lee EY, Restrepo R, et al. Hip disorders in children. AJR Am J Roentgenol. 2013;201:W776-796. doi: 10.2214/AJR.13.10623
  155. Handa R, Upadhyaya S, Kapoor S, et al. Tuberculosis and biologics in rheumatology: A special situation. Int J Rheum Dis. 2017;20:1313–25. doi: 10.1111/1756-185X.13129
  156. Cantini F, Nannini C, Niccoli L, et al. Guidance for the management of patients with latent tuberculosis infection requiring biologic therapy in rheumatology and dermatology clinical practice. Autoimmun Rev. 2015;14:503–9. doi: 10.1016/j.autrev.2015.01.011
  157. Clemente D, Cuadros EN, Lovillo MC, et al. Position statement on infection screening, prophylaxis, and vaccination of pediatric patients with rheumatic diseases and immunosuppressive therapies, part 3: precautions in situations of surgery, fever, and opportunistic infections. Eur J Pediatr. 2023;183:915–27. doi: 10.1007/s00431-023-05295-4
  158. Bovid KM, Moore MD. Juvenile Idiopathic Arthritis for the Pediatric Orthopedic Surgeon. Orthop Clin North Am. 2019;50:471–88. doi: 10.1016/j.ocl.2019.06.003
  159. Clarke SLN, Sen ES, Ramanan AV. Juvenile idiopathic arthritis-associated uveitis. Pediatr Rheumatol. 2016;14:27. doi: 10.1186/s12969-016-0088-2
  160. Garbrecht JL, Powell ZR, McClard CK, et al. Frosted branch angiitis in a patient with systemic juvenile idiopathic arthritis: a case report. BMC Ophthalmol. 2024;24:106. doi: 10.1186/s12886-024-03373-1
  161. Radwan‐Oczko M, Duś‐Ilnicka I, Richards P, et al. Rheumatoid arthritis patients’ oral health and disease activity. Int J Rheum Dis. 2019;22:1538–43. doi: 10.1111/1756-185X.13590
  162. Lvovich S, Goldsmith DP. Neurological Complications of Rheumatic Disease. Semin Pediatr Neurol. 2017;24:54–9. doi: 10.1016/j.spen.2016.12.007
  163. Shiari R. Neurologic manifestations of childhood rheumatic diseases. Iran J Child Neurol. 2012;6:1–7.
  164. Ben-Chetrit E, Gattorno M, Gul A, et al. Consensus proposal for taxonomy and definition of the autoinflammatory diseases (AIDs): a Delphi study. Ann Rheum Dis. 2018;77:1558–65. doi: 10.1136/annrheumdis-2017-212515
  165. Dumas G, Arabi YM, Bartz R, et al. Diagnosis and management of autoimmune diseases in the ICU. Intensive Care Med. 2024;50:17–35. doi: 10.1007/s00134-023-07266-7
  166. Röher K, Trieschmann U, Leister N. Anästhesie und Analgosedierung für diagnostische Eingriffe bei Kindern. AINS - Anästhesiol · Intensivmed · Notfallmedizin · Schmerzther. 2023;58:409–20. doi: 10.1055/a-1925-7009
  167. Janssen NM, Karnad DR, Guntupalli KK. Rheumatologic diseases in the intensive care unit: epidemiology, clinical approach, management, and outcome. Crit Care Clin. 2002;18:729–48. doi: 10.1016/S0749-0704(02)00025-8
  168. Hynes L, Saetes S, McGuire B, et al. Child and Family Adaptation to Juvenile Idiopathic Arthritis—A Systematic Review of the Role of Resilience Resources and Mechanisms. Front Psychol. 2019;10:2445. doi: 10.3389/fpsyg.2019.02445
  169. Frye WS, Milojevic D. The Role of Psychology in Pediatric Rheumatic Diseases. Pediatr Clin North Am. 2022;69:965–74. doi: 10.1016/j.pcl.2022.05.009
  170. Chyzheuskaya I. et al. THU0508 Psychological features of children with rheumatic diseases. – 2017.
  171. LeBovidge JS. Psychological Adjustment of Children and Adolescents WithChronic Arthritis: A Meta-analytic Review. J Pediatr Psychol. 2003;28:29–39. doi: 10.1093/jpepsy/28.1.29
  172. Ferro MA, Boyle MH. Self-concept among youth with a chronic illness: A meta-analytic review. Health Psychol. 2013;32:839–48. doi: 10.1037/a0031861
  173. Cousino MK, Hazen RA. Parenting Stress Among Caregivers of Children With Chronic Illness: A Systematic Review. J Pediatr Psychol. 2013;38:809–28. doi: 10.1093/jpepsy/jst049
  174. Knafl K, Leeman J, Havill NL, et al. The Contribution of Parent and Family Variables to the Well-Being of Youth With Arthritis. J Fam Nurs. 2015;21:579–616. doi: 10.1177/1074840715601475
  175. Yamaguchi M, Ohta A, Tsunematsu T, et al. Preliminary criteria for classification of adult Still’s disease. J Rheumatol. 1992;19:424–30.
  176. Martini A, Ravelli A, Avcin T, et al. Toward New Classification Criteria for Juvenile Idiopathic Arthritis: First Steps, Pediatric Rheumatology International Trials Organization International Consensus. J Rheumatol. 2019;46:190–7. doi: 10.3899/jrheum.180168
  177. Ravelli A, Davì S, Minoia F, et al. Macrophage Activation Syndrome. Hematol Oncol Clin North Am. 2015;29:927–41. doi: 10.1016/j.hoc.2015.06.010
  178. Henderson LA, Cron RQ. Macrophage Activation Syndrome and Secondary Hemophagocytic Lymphohistiocytosis in Childhood Inflammatory Disorders: Diagnosis and Management. Pediatr Drugs. 2020;22:29–44. doi: 10.1007/s40272-019-00367-1
  179. Shakoory B, Carcillo JA, Chatham WW, et al. Interleukin-1 Receptor Blockade Is Associated With Reduced Mortality in Sepsis Patients With Features of Macrophage Activation Syndrome: Reanalysis of a Prior Phase III Trial*. Crit Care Med. 2016;44:275–81. doi: 10.1097/CCM.0000000000001402
  180. Hines MR, von Bahr Greenwood T, Beutel G, et al. Consensus-Based Guidelines for the Recognition, Diagnosis, and Management of Hemophagocytic Lymphohistiocytosis in Critically Ill Children and Adults. Crit Care Med. 2022;50:860–72. doi: 10.1097/CCM.0000000000005361
  181. Avčin T, Tse SML, Schneider R, et al. Macrophage activation syndrome as the presenting manifestation of rheumatic diseases in childhood. J Pediatr. 2006;148:683–6. doi: 10.1016/j.jpeds.2005.12.070
  182. Lehmberg K, Pink I, Eulenburg C, et al. Differentiating Macrophage Activation Syndrome in Systemic Juvenile Idiopathic Arthritis from Other Forms of Hemophagocytic Lymphohistiocytosis. J Pediatr. 2013;162:1245–51. doi: 10.1016/j.jpeds.2012.11.081
  183. Yokoyama T, Shimizu M, Ikeno I, et al. [Case of systemic-onset juvenile idiopathic arthritis complicated with sepsis --usefulness of cytokine profile for the differentiation between macrophage activation syndrome and sepsis]. Nihon Rinsho Meneki Gakkai Kaishi. 2011;34:105–11. doi: 10.2177/jsci.34.105
  184. Chen T-Y, Hsu M-H, Kuo H-C, et al. Outcome analysis of pediatric hemophagocytic lymphohistiocytosis. J Formos Med Assoc. 2021;120:172–9. doi: 10.1016/j.jfma.2020.03.025
  185. Rajagopal R, Thachil J, Monagle P. Disseminated intravascular coagulation in paediatrics. Arch Dis Child. 2017;102:187–93. doi: 10.1136/archdischild-2016-311053
  186. Rigante D, Emmi G, Fastiggi M, et al. Macrophage activation syndrome in the course of monogenic autoinflammatory disorders. Clin Rheumatol. 2015;34:1333–9. doi: 10.1007/s10067-015-2923-0
  187. Valade S, Mariotte E, Azoulay E. Coagulation Disorders in Hemophagocytic Lymphohistiocytosis/Macrophage Activation Syndrome. Crit Care Clin. 2020;36:415–26. doi: 10.1016/j.ccc.2019.12.004
  188. Shakoory B, Geerlinks A, Wilejto M, et al. The 2022 EULAR/ACR points to consider at the early stages of diagnosis and management of suspected haemophagocytic lymphohistiocytosis/macrophage activation syndrome (HLH/MAS). Ann Rheum Dis. 2023;82:1271–85. doi: 10.1136/ard-2023-224123
  189. Valade S, Azoulay E, Galicier L, et al. Coagulation Disorders and Bleedings in Critically Ill Patients With Hemophagocytic Lymphohistiocytosis. Medicine (Baltimore). 2015;94:e1692. doi: 10.1097/MD.0000000000001692
  190. Li Z, Xiao J, Song H, et al. Evaluation of coagulation disorders by thromboelastography in children with systemic lupus erythematosus. Lupus. 2019;28:181–8. doi: 10.1177/0961203318819137
  191. Sepúlveda M P, Salgado U A, Barriga G J, et al. Usefulness of the thromboelastogram in children: correlation with habitual coagulation tests. Rev Chil Pediatr. 2019;90:617–23. doi: 10.32641/rchped.v90i6.930
  192. Law C, Raffini L. A Guide to the Use of Anticoagulant Drugs in Children. Pediatr Drugs. 2015;17:105–14. doi: 10.1007/s40272-015-0120-x
  193. Bagri NK, Gupta L, Sen ES, et al. Macrophage Activation Syndrome in Children: Diagnosis and Management. Indian Pediatr. 2021;58:1155–61. doi: 10.1007/s13312-021-2399-8
  194. Abolghasemi H, Shahverdi E, Niknam R, et al. Macrophage Activation Syndrome as the First Presentation of Juvenile Idiopathic Arthritis. IJBC. 2017;9:93–6.
  195. Ansuini V, Rigante D, Esposito S. Debate around infection-dependent hemophagocytic syndrome in paediatrics. BMC Infect Dis. 2013;13:15. doi: 10.1186/1471-2334-13-15
  196. D’Errico MM, Cuoco F, Biancardi C, et al. YIM-P58. Macrophage activation syndrome: the role of infectious triggers. Pediatr Rheumatol. 2014;12:Y5, 1546-0096-12-S1-Y5. doi: 10.1186/1546-0096-12-S1-Y5
  197. Eloseily EM, Cron RQ. Macrophage Activation Syndrome. In: Ragab G, Atkinson TP, Stoll ML, eds. The Microbiome in Rheumatic Diseases and Infection. Cham: Springer International Publishing 2018:151–82.
  198. Long S. S., Pickering L. K., Prober C. G. Principles and practice of pediatric infectious diseases. – 2023.
  199. Xu D, Li S, Chen Z, et al. Detection of Mycoplasma pneumoniae in different respiratory specimens. Eur J Pediatr. 2011;170:851–8. doi: 10.1007/s00431-010-1360-y
  200. Copete AR, Vera C, Herrera M, et al. Mycoplasma pneumoniae in Children With and Without Community-acquired Pneumonia. What do PCR and Serology Say? Pediatr Infect Dis J. 2020;39:e104–8. doi: 10.1097/INF.0000000000002636
  201. Waris ME, Toikka P, Saarinen T, et al. Diagnosis of Mycoplasma pneumoniae Pneumonia in Children. J Clin Microbiol. 1998;36:3155–9. doi: 10.1128/JCM.36.11.3155-3159.1998
  202. Department of Microbiology, Maulana Azad Medical College, India, Kumar S, Kumar S, et al. Mycoplasma Pneumoniae as a Causative Agent of Community-Acquired Lower Respiratory Tract Infections in Children. Ann Pediatr Child Health. 2023;11:1–4. doi: 10.47739/2373-9312.pediatrics.1325
  203. Blanche S, Caniglia M, Fischer A, et al. Epstein-Barr Virus-Associated Hemophagocytic Syndrome: Clinical Presentation and Treatment. Pediatr Hematol Oncol. 1989;6:233–5. doi: 10.3109/08880018909034292
  204. Nowalk A, Green M. Epstein-Barr Virus. Microbiol Spectr. 2016;4:4.3.47. doi: 10.1128/microbiolspec.DMIH2-0011-2015
  205. Zeng H-S, Xiong X-Y, Wei Y-D, et al. Macrophage activation syndrome in 13 children with systemic-onset juvenile idiopathic arthritis. World J Pediatr. 2008;4:97–101. doi: 10.1007/s12519-008-0018-6
  206. Brisse E, Matthys P, Wouters CH. Understanding the spectrum of haemophagocytic lymphohistiocytosis: update on diagnostic challenges and therapeutic options. Br J Haematol. 2016;174:175–87. doi: 10.1111/bjh.14144
  207. Lukjanoviča K, Šlēziņa I, Dāvidsone Z, et al. Systemic Juvenile Idiopathic Arthritis and Secondary Macrophage Activation Syndrome in Latvia from 2009 to 2020: A Nationwide Retrospective Study. Medicina (Mex). 2023;59:798. doi: 10.3390/medicina59040798
  208. Nadimpalli S, Foca M, Satwani P, et al. Diagnostic yield of bronchoalveolar lavage in immunocompromised children with malignant and non-malignant disorders: BAL in Immunocompromised Children. Pediatr Pulmonol. 2017;52:820–6. doi: 10.1002/ppul.23644
  209. Ers. Bronchoalveolar lavage in children. Eur Respir J. 2000;15:217–31. doi: 10.1183/09031936.00.15121700
  210. Amanati A, Karimi A, Fahimzad A, et al. Prevalence of Human Herpes Viruses in Bronchoalveolar Lavage of Critically Ill Children Undergoing Mechanical Ventilation at a Pediatric Intensive Care Unit. Arch Pediatr Infect Dis. 2018;6. doi: 10.5812/pedinfect.12685
  211. Wong JCP, Hon KLE, Leung KKY, et al. Diagnostic Yield of Bronchoalveolar Lavage in Immunocompromised Children. J Trop Pediatr. 2021;67:fmaa131. doi: 10.1093/tropej/fmaa131
  212. Özkoç S, Bayram Deli̇Baş S. Investigation of Pneumocystis jirovecii Pneumonia and Colonization in Iatrogenically Immunosuppressed and Immunocompetent Patients. Mikrobiyol Bul. 2015;49:221–30. doi: 10.5578/mb.9344
  213. Eroglu‐Ertugrul NG, Yalcin E, Oguz B, et al. The value of flexible bronchoscopy in pulmonary infections of immunosuppressed children. Clin Respir J. 2020;14:78–84. doi: 10.1111/crj.13103
  214. Gonski K, Cohn R, Widger J, et al. Utility of bronchoscopy in immunocompromised paediatric patients: Systematic review. Paediatr Respir Rev. 2020;34:24–34. doi: 10.1016/j.prrv.2020.02.003
  215. Lachant DJ, Croft DP, McGrane Minton H, et al. The clinical impact of pneumocystis and viral PCR testing on bronchoalveolar lavage in immunosuppressed patients. Respir Med. 2018;145:35–40. doi: 10.1016/j.rmed.2018.10.021
  216. Varadaraju S, Khandelwal P, Sankar J, et al. Multiple opportunistic infection-associated hemophagocytic lymphohistiocytosis in nephrotic syndrome: A case report. J Pediatr Crit Care. 2021;8:295. doi: 10.4103/jpcc.jpcc_64_21
  217. Weyant RB, Kabbani D, Doucette K, et al. Pneumocystis jirovecii: a review with a focus on prevention and treatment. Expert Opin Pharmacother. 2021;22:1579–92. doi: 10.1080/14656566.2021.1915989
  218. Morris A, Norris KA. Colonization by Pneumocystis jirovecii and Its Role in Disease. Clin Microbiol Rev. 2012;25:297–317. doi: 10.1128/CMR.00013-12
  219. White PL, Price JS, Backx M. Pneumocystis jirovecii Pneumonia: Epidemiology, Clinical Manifestation and Diagnosis. Curr Fungal Infect Rep. 2019;13:260–73. doi: 10.1007/s12281-019-00349-3
  220. Schüller M, Macků M, Fráňová J. Pneumocystis pneumonia in a child with sojia. Pediatr Rheumatol. 2014;12:P225, 1546-0096-12-S1-P225. doi: 10.1186/1546-0096-12-S1-P225
  221. Saper V. E. et al. Emergent high fatality lung disease in systemic juvenile arthritis //Annals of the rheumatic diseases. – 2019. – Т. 78. – №. 12. – С. 1722-1731.
  222. Rayment JH, Narang I. Pulmonary Aspergillosis in a Previously Healthy 13-Year-Old Boy. Can Respir J. 2016;2016:4575942. doi: 10.1155/2016/4575942
  223. de Mol M, de Jongste JC, van Westreenen M, et al. Diagnosis of invasive pulmonary aspergillosis in children with bronchoalveolar lavage galactomannan: BAL Galactomannan Aspergillosis Children. Pediatr Pulmonol. 2013;48:789–96. doi: 10.1002/ppul.22670
  224. Zhao M, Guan Y, Lin J, et al. Acute kidney injury in critical care: complications of hemophagocytic lymphohistiocytosis. Front Immunol. 2024;15:1396124. doi: 10.3389/fimmu.2024.1396124
  225. Fitzgerald NE, MacClain KL. Imaging characteristics of hemophagocytic lymphohistiocytosis. Pediatr Radiol. 2003;33:392–401. doi: 10.1007/s00247-003-0894-9
  226. Schmidt MH, Sung L, Shuckett BM. Hemophagocytic Lymphohistiocytosis in Children: Abdominal US Findings within 1 Week of Presentation. Radiology. 2004;230:685–9. doi: 10.1148/radiol.2303030223
  227. Chinnici A, Beneforti L, Pegoraro F, et al. Approaching hemophagocytic lymphohistiocytosis. Front Immunol. 2023;14:1210041. doi: 10.3389/fimmu.2023.1210041
  228. Malik P, Antonini L, Mannam P, et al. MRI Patterns in Pediatric CNS Hemophagocytic Lymphohistiocytosis. Am J Neuroradiol. 2021;42:2077–85. doi: 10.3174/ajnr.A7292
  229. Shieh AC, Guler E, Smith DA, et al. Hemophagocytic Lymphohistiocytosis: A Primer for Radiologists. Am J Roentgenol. 2020;214:W11–9. doi: 10.2214/AJR.19.21788
  230. Hur M, Kim YC, Lee KM, et al. Macrophage Activation Syndrome in a Child with Systemic Juvenile Rheumatoid Arthritis. J Korean Med Sci. 2005;20:695. doi: 10.3346/jkms.2005.20.4.695
  231. Behrens EM, Beukelman T, Paessler M, et al. Occult macrophage activation syndrome in patients with systemic juvenile idiopathic arthritis. J Rheumatol. 2007;34:1133–8.
  232. Shekarchian F, Abadi MKA, Shariati MM. Clinical approach to a child with hemophagocytic lymphohistiocytosis and bilateral optic nerve head infiltration: A case report and brief literature review. Clin Case Rep. 2023;11:e7999. doi: 10.1002/ccr3.7999
  233. Wang L, Suo L, Kou F, et al. Ocular Phenotypes in Patients With Hemophagocytic Lymphohistiocytosis: A Retrospective Analysis in a Single Center Over 7 Years. Am J Ophthalmol. 2023;253:119–31. doi: 10.1016/j.ajo.2023.05.011
  234. García-Domínguez M. et al. Atypical eye manifestation in macrophage activation syndrome complicating systemic juvenile idiopathic arthritis //Alergia, Asma e Inmunología Pediátricas. – 2020. – Т. 29. – №. 2. – С. 66-70.
  235. Ravelli A, Minoia F, Davì S, et al. 2016 Classification Criteria for Macrophage Activation Syndrome Complicating Systemic Juvenile Idiopathic Arthritis: A European League Against Rheumatism/American College of Rheumatology/Paediatric Rheumatology International Trials Organisation Collaborative Initiative. Ann Rheum Dis. 2016;75:481–9. doi: 10.1136/annrheumdis-2015-208982
  236. Криулин И.А., Алексеева Е.И., Шилькрот И.Ю., Дворяковская Т.М. Вторичный гемофагоцитарный синдром: прогностическая модель и ранние маркеры развития у пациентов с системным ювенильным идиопатическим артритом. Результаты когортного ретроспективного исследования. Вопросы практической педиатрии. 2022; 17(6): 17–24. DOI: 10.20953/1817-7646-2022-6-17-24
  237. Onel K, Rumsey DG, Shenoi S. Juvenile Idiopathic Arthritis Treatment Updates. Rheum Dis Clin N Am. 2021;47:545–63. doi: 10.1016/j.rdc.2021.07.009
  238. Pan S, Yu H, Surti A, et al. Pharmacodynamics of rituximab on B lymphocytes in paediatric patients with autoimmune diseases. Br J Clin Pharmacol. 2019;85:1790–7. doi: 10.1111/bcp.13970
  239. McAtee CL, Lubega J, Underbrink K, et al. Association of Rituximab Use With Adverse Events in Children, Adolescents, and Young Adults. JAMA Netw Open. 2021;4:e2036321. doi: 10.1001/jamanetworkopen.2020.36321
  240. Smolewska E, Cebula B, Brózik H, et al. Relationship between impaired apoptosis of lymphocytes and distribution of dendritic cells in peripheral blood and synovial fluid of children with juvenile idiopathic arthritis. Arch Immunol Ther Exp (Warsz). 2008;56:283–9. doi: 10.1007/s00005-008-0030-5
  241. Bateman M, Oladele R, Kolls JK. Diagnosing Pneumocystis jirovecii pneumonia: A review of current methods and novel approaches. Med Mycol. 2020;58:1015–28. doi: 10.1093/mmy/myaa024
  242. Park JW, Curtis JR, Kim MJ, et al. Pneumocystis pneumonia in patients with rheumatic diseases receiving prolonged, non-high-dose steroids—clinical implication of primary prophylaxis using trimethoprim–sulfamethoxazole. Arthritis Res Ther. 2019;21:207. doi: 10.1186/s13075-019-1996-6
  243. Sulieman SE, Metjian TA, Zaoutis TE, et al. Pneumocystis Pneumonia: Epidemiology and Options for Prophylaxis in Non-HIV Immunocompromised Pediatric Patients. Curr Fungal Infect Rep. 2014;8:45–55. doi: 10.1007/s12281-014-0177-y
  244. García-Moreno J, Melendo-Pérez S, Martín-Gómez MT, et al. Pneumocystis jirovecii pneumonia in children. A retrospective study in a single center over three decades. Enfermedades Infecc Microbiol Clínica. 2020;38:111–8. doi: 10.1016/j.eimc.2019.05.005
  245. Kim YW, Kwon BS, Lim SY, et al. Diagnostic value of bronchoalveolar lavage and bronchial washing in sputum-scarce or smear-negative cases with suspected pulmonary tuberculosis: a randomized study. Clin Microbiol Infect. 2020;26:911–6. doi: 10.1016/j.cmi.2019.11.013
  246. Daelemans, Siel & Peeters, Linde & Wachter, Elke & Malfroot, Anne. (2019). Challenges in Diagnosing Mycobacterial Infections in Children.. 21. 194-199.
  247. Solovic I, Sester M, Gomez-Reino JJ, et al. The risk of tuberculosis related to tumour necrosis factor antagonist therapies: a TBNET consensus statement. Eur Respir J. 2010;36:1185–206. doi: 10.1183/09031936.00028510
  248. Qu Y, Liu M, Sun X, et al. Development and evaluation of a triplex droplet digital PCR method for differentiation of M. tuberculosis, M. bovis and BCG. Front Microbiol. 2024;15:1397792. doi: 10.3389/fmicb.2024.1397792
  249. Bal ZS, Yazici P, Sen S, et al. A fatal case of tuberculous meningitis in a child with juvenile idiopathic arthritis: a diagnostic challenge. Rev Soc Bras Med Trop. 2017;50:709–11. doi: 10.1590/0037-8682-0410-2016
  250. Armbrust W, Kamphuis SSM, Wolfs TWF, et al. Tuberculosis in a nine-year-old girl treated with infliximab for systemic juvenile idiopathic arthritis. Rheumatology. 2004;43:527–9. doi: 10.1093/rheumatology/keh074
  251. Noguera-Julian A, Calzada-Hernández J, Brinkmann F, et al. Tuberculosis Disease in Children and Adolescents on Therapy With Antitumor Necrosis Factor-ɑ Agents: A Collaborative, Multicenter Paediatric Tuberculosis Network European Trials Group (ptbnet) Study. Clin Infect Dis. 2020;71:2561–9. doi: 10.1093/cid/ciz1138
  252. Restrepo-Gualteros SM, Gutierrez MJ, Villamil-Osorio M, et al. Challenges and Clinical Implications of the Diagnosis of Cytomegalovirus Lung Infection in Children. Curr Infect Dis Rep. 2019;21:24. doi: 10.1007/s11908-019-0681-x
  253. Lyu J, Deng Q, Li R, et al. Pneumonia Caused by Coinfection with Cytomegalovirus and Pneumocystis jirovecii in an HIV-Negative Infant Diagnosed by Metagenomic Next-Generation Sequencing. Infect Drug Resist. 2022;Volume 15:3417–25. doi: 10.2147/IDR.S364241
  254. Ramos JT, Romero CA, Belda S, et al. Clinical practice update of antifungal prophylaxis in immunocompromised children. Rev Espanola Quimioter Publicacion Of Soc Espanola Quimioter 2019;32:410–25.
  255. Tragiannidis A, Kyriakidis I, Zündorf I, et al. Invasive fungal infections in pediatric patients treated with tumor necrosis alpha (TNF-α) inhibitors. Mycoses. 2017;60:222–9. doi: 10.1111/myc.12576
  256. Lazzerini PE, Capecchi PL, Guideri F, et al. Comparison of Frequency of Complex Ventricular Arrhythmias in Patients With Positive Versus Negative Anti-Ro/SSA and Connective Tissue Disease. Am J Cardiol. 2007;100:1029–34. doi: 10.1016/j.amjcard.2007.04.048
  257. Caforio ALP, Adler Y, Agostini C, et al. Diagnosis and management of myocardial involvement in systemic immune-mediated diseases: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Disease. Eur Heart J. 2017;38:2649–62. doi: 10.1093/eurheartj/ehx321
  258. Sharma AP, Norozi K, Filler G, et al. Diagnosis of Pediatric Hypertension: European Society of Hypertension-recommended 24-hr vs. 24-hr-day-night Ambulatory Blood Pressure thresholds. ;23.
  259. Akça ÜK, Sökmen O, Bölek EÇ, et al. A case report of intracranial hypertension and aseptic meningitis: anti-tumor necrosis factor associated or juvenile idiopathic arthritis related. Turk J Pediatr. 2021;63:522–6. doi: 10.24953/turkjped.2021.03.022
  260. Zhang P, Li X, Li Y, et al. Reversible posterior leukoencephalopathy syndrome secondary to systemic-onset juvenile idiopathic arthritis: A case report and review of the literature. Biomed Rep. 2015;3:55–8. doi: 10.3892/br.2014.380
  261. Koenig MK, Perez M, Rothenberg S, et al. Juvenile Onset Central Nervous System Folate Deficiency and Rheumatoid Arthritis. J Child Neurol. 2008;23:106–7. doi: 10.1177/0883073807307986
  262. Coşkun AN, Günbey C, Göçmen R, et al. Concurrence of juvenile idiopathic arthritis and primary demyelinating disease in a young child. Mult Scler Relat Disord. 2019;27:20–2. doi: 10.1016/j.msard.2018.10.002
  263. Lourenço DMR, Buscatti IM, Lourenço B, et al. Neurite óptica em paciente com artrite idiopática juvenil. Rev Bras Reumatol. 2014;54:486–9. doi: 10.1016/j.rbr.2014.01.011
  264. Weng Y, Yi C, Liang H, et al. The Brain Structural-Functional Vulnerability in Drug-Naive Children With Juvenile Idiopathic Arthritis: Insights From the Hippocampus. Front Hum Neurosci. 2022;16:833602. doi: 10.3389/fnhum.2022.833602
  265. Cao Z-Y, Wang N, Jia J-T, et al. Abnormal topological organization in systemic lupus erythematosus: a resting-state functional magnetic resonance imaging analysis. Brain Imaging Behav. 2021;15:14–24. doi: 10.1007/s11682-019-00228-y
  266. Mavrogeni S, Koutsogeorgopoulou L, Dimitroulas T, et al. Combined Brain/Heart Magnetic Resonance Imaging in Systemic Lupus Erythematosus. Curr Cardiol Rev. 2020;16:178–86. doi: 10.2174/1573403X15666190801122105
  267. Goh YP, Naidoo P, Ngian G-S. Imaging of systemic lupus erythematosus. Part II: Gastrointestinal, renal, and musculoskeletal manifestations. Clin Radiol. 2013;68:192–202. doi: 10.1016/j.crad.2012.06.109
  268. Fotis L, Baszis KW, French AR, et al. Mesenteric vasculitis in children with systemic lupus erythematosus. Clin Rheumatol. 2016;35:785–93. doi: 10.1007/s10067-015-2892-3
  269. Lalani TA, Kanne JP, Hatfield GA, et al. Imaging Findings in Systemic Lupus Erythematosus. RadioGraphics. 2004;24:1069–86. doi: 10.1148/rg.244985082
  270. Zajaczkowska M, Papierkowski A, Szczepanowska A, et al. [Influence of glucocorticoid steroid therapy on gastric and duodenal mucosa and Helicobacter pylori infection in children with nephrotic syndrome]. Pol Merkur Lek Organ Pol Tow Lek. 2001;10:165–7.
  271. Wobma H, Bachrach R, Farrell J, et al. Development of a Screening Algorithm for Lung Disease in Systemic Juvenile Idiopathic Arthritis. ACR Open Rheumatol. 2023;5:556–62. doi: 10.1002/acr2.11600
  272. Galindo-Zavala R, Bou-Torrent R, Magallares-López B, et al. Expert panel consensus recommendations for diagnosis and treatment of secondary osteoporosis in children. Pediatr Rheumatol. 2020;18:20. doi: 10.1186/s12969-020-0411-9
  273. Buckley L, Guyatt G, Fink HA, et al. 2017 American College of Rheumatology Guideline for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis: ACR guideline for glucocorticoid-induced osteoporosis prevention and treatment. Arthritis Rheumatol. 2017;69:1521–37. doi: 10.1002/art.40137
  274. Harari S, Paciocco G, Aramu S. Ear and nose involvement in systemic diseases. Monaldi Arch Chest Dis Arch Monaldi Mal Torace. 2000;55:466–70.
  275. Stoustrup P, Resnick CM, Abramowicz S, et al. Management of Orofacial Manifestations of Juvenile Idiopathic Arthritis: Interdisciplinary Consensus‐Based Recommendations. Arthritis Rheumatol. 2023;75:4–14. doi: 10.1002/art.42338
  276. Walton AG, Welbury RR, Thomason JM, et al. Oral health and juvenile idiopathic arthritis: a review. Rheumatology. 2000;39:550–5. doi: 10.1093/rheumatology/39.5.550
  277. Whittle, Vanessa & Gane, J & Cheetham, T. (2017). G169(P) Management of steroid induced diabetes in children: A national perspective. Archives of Disease in Childhood. 102. A69.1-A69. 10.1136/archdischild-2017-313087.168.
  278. Fc A. The Portuguese Society of Rheumatology position paper on the use of biosimilars – 2017 update. 2017.
  279. Atzeni F, Sebastiani M, Ricci C, et al. Position paper of Italian rheumatologists on the use of biosimilar drugs.
  280. Abad Hernández MÁ, Andreu JL, Caracuel Ruiz MÁ, et al. Position Paper From the Spanish Society of Rheumatology on Biosimilar Drugs. Reumatol Clínica Engl Ed. 2015;11:269–78. doi: 10.1016/j.reumae.2015.03.012
  281. Huizinga TWJ, Torii Y, Muniz R. Adalimumab Biosimilars in the Treatment of Rheumatoid Arthritis: A Systematic Review of the Evidence for Biosimilarity. Rheumatol Ther. 2021;8:41–61. doi: 10.1007/s40744-020-00259-8
  282. Levy DM, Imundo LF. Nonsteroidal Anti-Inflammatory Drugs: A survey of practices and concerns of pediatric medical and surgical specialists and a summary of available safety data. Pediatr Rheumatol. 2010;8:7. doi: 10.1186/1546-0096-8-7
  283. Litalien C., Jacqz-Aigrain E. Risks and benefits of nonsteroidal anti-inflammatory drugs in children //Paediatric drugs. – 2001. – Т. 3. – №. 11. – С. 817-858.
  284. Hollingworth P. The use of non-steroidal anti-inflammatory drugs in paediatric rheumatic diseases //Rheumatology. – 1993. – Т. 32. – №. 1. – С. 73-77.
  285. Guillaume-Czitrom S. Les anti-inflammatoires non stéroïdiens dans les rhumatismes inflammatoires chroniques de l’enfant [Non -steroidal anti-inflammatory drugs in chronic inflammatory arthritis in children]. La Lettre du Rhumatologue №379-380 - février-mars 2012.
  286. Gupta P, Sachdev HP. Safety of oral use of nimesulide in children: systematic review of randomized controlled trials. Indian Pediatr. 2003 Jun;40(6):518-31. PMID: 12824661.
  287. Todd PA, Sorkin EM. Diclofenac Sodium: A Reappraisal of its Pharmacodynamic and Pharmacokinetic Properties, and Therapeutic Efficacy. Drugs. 1988;35:244–85. doi: 10.2165/00003495-198835030-00004
  288. Standing J. F. Diclofenac for acute pain in children: Pharmacokinetics and safety. – University of London, University College London (United Kingdom), 2007.
  289. Иосифовна АЕ, С.и В. Оценка эффективности, переносимости и безопасности нимесулида у детей с ювенильным артритом. Вопросы Современной Педиатрии. 2007;6:76–80.
  290. Sherman JM, Sood SK. Current challenges in the diagnosis and management of fever. Curr Opin Pediatr. 2012;24:400–6. doi: 10.1097/MOP.0b013e32835333e3
  291. Ringold S, Weiss PF, Beukelman T, et al. 2013 update of the 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: recommendations for the medical therapy of children with systemic juvenile idiopathic arthritis and tuberculosis screening among children receiving biologic medications. Arthritis Care Res. 2013;65:1551–63. doi: 10.1002/acr.22087
  292. Beukelman T, Patkar NM, Saag KG, et al. 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features. Arthritis Care Res. 2011;63:465–82. doi: 10.1002/acr.20460
  293. Adiguzel Dundar H, Acari C, Turkucar S, et al. Treatment of systemic JIA: When do we need a biologic? Real world data of a single center. Mod Rheumatol. 2021;31:684–90. doi: 10.1080/14397595.2020.1761079
  294. Hinze CH, Foell D, Kessel C. Treatment of systemic juvenile idiopathic arthritis. Nat Rev Rheumatol. 2023;19:778–89. doi: 10.1038/s41584-023-01042-z
  295. Vannucci G, Cantarini L, Giani T, et al. Glucocorticoids in the Management of Systemic Juvenile Idiopathic Arthritis. Pediatr Drugs. 2013;15:343–9. doi: 10.1007/s40272-013-0038-0
  296. Grevich S, Shenoi S. Update on the management of systemic juvenile idiopathic arthritis and role of IL-1 and IL-6 inhibition. Adolesc Health Med Ther. 2017;8:125–35. doi: 10.2147/AHMT.S109495
  297. Jones AP, Clayton D, Nkhoma G, et al. Different corticosteroid induction regimens in children and young people with juvenile idiopathic arthritis: the SIRJIA mixed-methods feasibility study. Health Technol Assess. 2020;24:1–152. doi: 10.3310/hta24360
  298. https://neo.barnlakarforeningen.se/wp-content/uploads/sites/11/2015/05/Medical-treatment-of-juvenile-idiopathic-arthritis.pdf https://pubmed.ncbi.nlm.nih.gov/15252213/.
  299. Rubin S, Ohana O, Goldberg O, et al. The efficacy and safety of intra-articular injection of triamcinolone acetonide versus triamcinolone hexacetonide for treatment of juvenile idiopathic arthritis. Pediatr Rheumatol. 2022;20:5. doi: 10.1186/s12969-022-00666-x
  300. Zulian F. Triamcinolone acetonide and hexacetonide intra-articular treatment of symmetrical joints in juvenile idiopathic arthritis: a double-blind trial. Rheumatology. 2004;43:1288–91. doi: 10.1093/rheumatology/keh313
  301. Hetland ML, Stengaard-Pedersen K, Junker P, et al. Combination treatment with methotrexate, cyclosporine, and intraarticular betamethasone compared with methotrexate and intraarticular betamethasone in early active rheumatoid arthritis: An investigator-initiated, multicenter, randomized, double-blind, parallel-group, placebo-controlled study. Arthritis Rheum. 2006;54:1401–9. doi: 10.1002/art.21796
  302. Scherer J, Rainsford KD, Kean CA, et al. Pharmacology of intra-articular triamcinolone. Inflammopharmacology. 2014;22:201–17. doi: 10.1007/s10787-014-0205-0
  303. Zulian F, Martini G, Gobber D, et al. Comparison of intra-articular triamcinolone hexacetonide and triamcinolone acetonide in oligoarticular juvenile idiopathic arthritis. Rheumatol Oxf Engl. 2003;42:1254–9. doi: 10.1093/rheumatology/keg358
  304. Textbook of Pediatric Rheumatology. Elsevier 2016.
  305. Ferrara G, Mastrangelo G, Barone P, et al. Methotrexate in juvenile idiopathic arthritis: advice and recommendations from the MARAJIA expert consensus meeting. Pediatr Rheumatol Online J. 2018;16:46. doi: 10.1186/s12969-018-0255-8
  306. Ruperto N, Murray KJ, Gerloni V, et al. A randomized trial of parenteral methotrexate comparing an intermediate dose with a higher dose in children with juvenile idiopathic arthritis who failed to respond to standard doses of methotrexate. Arthritis Rheum. 2004;50:2191–201. doi: 10.1002/art.20288
  307. Giannini EH, Brewer EJ, Kuzmina N, et al. Methotrexate in Resistant Juvenile Rheumatoid Arthritis: Results of the U.S.A.–U.S.S.R. Double-Blind, Placebo-Controlled Trial. N Engl J Med. 1992;326:1043–9. doi: 10.1056/NEJM199204163261602
  308. Ravelli, A., Migliavacca, D., Viola, S., Ruperto, N., Pistorio, A., & Martini, A. (1999). Efficacy of folinic arid in reducing methotrexate toxicity in juvenile idiopathic arthritis. Clinical and experimental rheumatology, 17, 625-627.
  309. LRI Children’s Hospital Paediatric Rheumatology Methotrexate therapy/ url https://secure.library.leicestershospitals.nhs.uk/PAGL/Shared%20Documents/Methotrexate%20Therapy%20in%20Paediatric%20Rheumatology%20UHL%20Childrens%20Hospital%20Guideline.pdf.
  310. Niehues T, Lankisch P. Recommendations for the Use of Methotrexate in Juvenile Idiopathic Arthritis: Pediatr Drugs. 2006;8:347–56. doi: 10.2165/00148581-200608060-00003
  311. Calvo I, Antón J, López Robledillo JC, et al. Recomendaciones para el uso de metotrexato en pacientes con artritis idiopática juvenil. An Pediatría. 2016;84:177.e1-177.e8. doi: 10.1016/j.anpedi.2015.05.005
  312. Foeldvari I, Wierk A. Effectiveness of leflunomide in patients with juvenile idiopathic arthritis in clinical practice. J Rheumatol. 2010;37:1763–7. doi: 10.3899/jrheum.090874
  313. Ringold S, Angeles‐Han ST, Beukelman T, et al. 2019 American College of Rheumatology/Arthritis Foundation Guideline for the Treatment of Juvenile Idiopathic Arthritis: Therapeutic Approaches for Non‐Systemic Polyarthritis, Sacroiliitis, and Enthesitis. Arthritis Care Res. 2019;71:717–34. doi: 10.1002/acr.23870
  314. Harris JG, Kessler EA, Verbsky JW. Update on the treatment of juvenile idiopathic arthritis. Curr Allergy Asthma Rep. 2013;13:337–46. doi: 10.1007/s11882-013-0351-2
  315. Kimura Y, Beukelman T, Morgan-DeWitt E, et al. Results from the Childhood Arthritis and Rheumatology Research Alliance Systemic JIA Consensus Treatment Plans Pilot Study. ACR Meeting Abstracts. San Francisco, CA 2015.
  316. Nigrovic PA. Review: is there a window of opportunity for treatment of systemic juvenile idiopathic arthritis? Arthritis Rheumatol Hoboken NJ. 2014;66:1405–13. doi: 10.1002/art.38615
  317. Ravelli A, Consolaro A, Horneff G, et al. Treating juvenile idiopathic arthritis to target: recommendations of an international task force. Ann Rheum Dis. 2018;77:819–28. doi: 10.1136/annrheumdis-2018-213030
  318. Tarp S, Amarilyo G, Foeldvari I, et al. Efficacy and safety of biological agents for systemic juvenile idiopathic arthritis: a systematic review and meta-analysis of randomized trials. Rheumatol Oxf Engl. 2016;55:669–79. doi: 10.1093/rheumatology/kev382
  319. Yokota S, Itoh Y, Morio T, et al. Tocilizumab in systemic juvenile idiopathic arthritis in a real-world clinical setting: results from 1 year of postmarketing surveillance follow-up of 417 patients in Japan. Ann Rheum Dis. 2016;75:1654–60. doi: 10.1136/annrheumdis-2015-207818
  320. Ruperto N, Brunner HI, Ramanan AV, et al. Subcutaneous dosing regimens of tocilizumab in children with systemic or polyarticular juvenile idiopathic arthritis. Rheumatology. 2021;60:4568–80. doi: 10.1093/rheumatology/keab047
  321. Arthur VL, Shuldiner E, Remmers EF, et al. IL1RN Variation Influences Both Disease Susceptibility and Response to Recombinant Human Interleukin-1 Receptor Antagonist Therapy in Systemic Juvenile Idiopathic Arthritis. Arthritis Rheumatol Hoboken NJ. 2018;70:1319–30. doi: 10.1002/art.40498
  322. Grom AA, Ilowite NT, Pascual V, et al. Rate and Clinical Presentation of Macrophage Activation Syndrome in Patients With Systemic Juvenile Idiopathic Arthritis Treated With Canakinumab. Arthritis Rheumatol Hoboken NJ. 2016;68:218–28. doi: 10.1002/art.39407
  323. Nishimura K, Hara R, Umebayashi H, et al. Efficacy and safety of canakinumab in systemic juvenile idiopathic arthritis: 48-week results from an open-label phase III study in Japanese patients. Mod Rheumatol. 2021;31:226–34. doi: 10.1080/14397595.2020.1783163
  324. Mejbri M, Theodoropoulou K, Hofer M, et al. Interleukin-1 Blockade in Systemic Juvenile Idiopathic Arthritis. Pediatr Drugs. 2020;22:251–62. doi: 10.1007/s40272-020-00392-5
  325. Swart JF, Barug D, Möhlmann M, et al. The efficacy and safety of interleukin-1-receptor antagonist anakinra in the treatment of systemic juvenile idiopathic arthritis. Expert Opin Biol Ther. 2010;10:1743–52. doi: 10.1517/14712598.2010.532785
  326. Wallace CA, Giannini EH, Huang B, et al. American College of Rheumatology provisional criteria for defining clinical inactive disease in select categories of juvenile idiopathic arthritis. Arthritis Care Res. 2011;63:929–36. doi: 10.1002/acr.20497
  327. Alexeeva EI, Valieva SI, Bzarova TM, et al. Efficacy and safety of repeat courses of rituximab treatment in patients with severe refractory juvenile idiopathic arthritis. Clin Rheumatol. 2011;30:1163–72. doi: 10.1007/s10067-011-1720-7
  328. Feito JG, Pereda CA. Rituximab therapy produced rapid and sustained clinical improvement in a patient with systemic onset juvenile idiopathic arthritis refractory to TNF alpha antagonists. J Clin Rheumatol Pract Rep Rheum Musculoskelet Dis. 2009;15:363–5. doi: 10.1097/RHU.0b013e3181ba3c6f
  329. Kaegi C, Wuest B, Schreiner J, et al. Systematic Review of Safety and Efficacy of Rituximab in Treating Immune-Mediated Disorders. Front Immunol. 2019;10:1990. doi: 10.3389/fimmu.2019.01990
  330. Kearsley-Fleet L, Sampath S, McCann LJ, et al. Use and effectiveness of rituximab in children and young people with juvenile idiopathic arthritis in a cohort study in the United Kingdom. Rheumatol Oxf Engl. 2019;58:331–5. doi: 10.1093/rheumatology/key306
  331. Narváez J, Díaz-Torné C, Juanola X, et al. Rituximab therapy for refractory systemic-onset juvenile idiopathic arthritis. Ann Rheum Dis. 2009;68:607–8. doi: 10.1136/ard.2008.092106
  332. Алексеева Е. И. и др. Эффективность и безопасность длительного применения ритуксимаба у пациентов с системным ювенильным идиопатическим артритом //Вопросы современной педиатрии. – 2013. – Т. 12. – №. 2. – С. 89-100.
  333. Brunner HI, Ruperto N, Tzaribachev N, et al. Subcutaneous golimumab for children with active polyarticular-course juvenile idiopathic arthritis: results of a multicentre, double-blind, randomised-withdrawal trial. Ann Rheum Dis. 2018;77:21–9. doi: 10.1136/annrheumdis-2016-210456
  334. Lovell DJ, Giannini EH, Reiff A, et al. Etanercept in children with polyarticular juvenile rheumatoid arthritis. Pediatric Rheumatology Collaborative Study Group. N Engl J Med. 2000;342:763–9. doi: 10.1056/NEJM200003163421103
  335. Lovell DJ, Ruperto N, Goodman S, et al. Adalimumab with or without methotrexate in juvenile rheumatoid arthritis. N Engl J Med. 2008;359:810–20. doi: 10.1056/NEJMoa0706290
  336. Otten MH, Anink J, Spronk S, et al. Efficacy of biological agents in juvenile idiopathic arthritis: a systematic review using indirect comparisons. Ann Rheum Dis. 2013;72:1806–12. doi: 10.1136/annrheumdis-2012-201991
  337. PRO-KIND SJIA project collaborators, Hinze CH, Holzinger D, et al. Practice and consensus-based strategies in diagnosing and managing systemic juvenile idiopathic arthritis in Germany. Pediatr Rheumatol. 2018;16:7. doi: 10.1186/s12969-018-0224-2
  338. Strand V, Balsa A, Al-Saleh J, et al. Immunogenicity of Biologics in Chronic Inflammatory Diseases: A Systematic Review. BioDrugs Clin Immunother Biopharm Gene Ther. 2017;31:299–316. doi: 10.1007/s40259-017-0231-8
  339. Wang B, Zhang Y, Zhao Z, et al. Comparative efficacy and safety of different drugs in patients with systemic juvenile idiopathic arthritis: A systematic review and network meta-analysis. Medicine (Baltimore). 2024;103:e38002. doi: 10.1097/MD.0000000000038002
  340. Tarp S, Amarilyo G, Foeldvari I, et al. Efficacy and safety of biological agents for systemic juvenile idiopathic arthritis: a systematic review and meta-analysis of randomized trials. Rheumatology. 2016;55:669–79. doi: 10.1093/rheumatology/kev382
  341. Diener C, Horneff G. Comparison of adverse events of biologicals for treatment of juvenile idiopathic arthritis: a systematic review. Expert Opin Drug Saf. 2019;18:719–32. doi: 10.1080/14740338.2019.1632288
  342. Amarilyo G, Tarp S, Foeldvari I, et al. Biological agents in polyarticular juvenile idiopathic arthritis: A meta-analysis of randomized withdrawal trials. Semin Arthritis Rheum. 2016;46:312–8. doi: 10.1016/j.semarthrit.2016.07.001
  343. Okamoto N, Yokota S, Takei S, et al. Clinical practice guidance for juvenile idiopathic arthritis (JIA) 2018. Mod Rheumatol. 2019;29:41–59. doi: 10.1080/14397595.2018.1514724
  344. Prince FHM, Twilt M, Cate RT, et al. Long-term follow-up on effectiveness and safety of etanercept in juvenile idiopathic arthritis: the Dutch national register. Ann Rheum Dis. 2009;68:635–41. doi: 10.1136/ard.2007.087411
  345. Emery P, Fleischmann RM, Moreland LW, et al. Golimumab, a human anti–tumor necrosis factor α monoclonal antibody, injected subcutaneously every four weeks in methotrexate‐naive patients with active rheumatoid arthritis: Twenty‐four–week results of a phase III, multicenter, randomized, double‐blind, placebo‐controlled study of golimumab before methotrexate as first‐line therapy for early‐onset rheumatoid arthritis. Arthritis Rheum. 2009;60:2272–83. doi: 10.1002/art.24638
  346. Инструкция по применению лекарственного препарата Энбрел ЛП-0021220931121.
  347. Инструкция по применению лекарственного препарата Этанерцепт ПСК ЛП-007057-310521.
  348. Инструкция по применению лекарственного препарата Эрелзи ЛП-006650-141220.
  349. Инструкция по применению лекарственного препарата Энбрел ЛСР-006652/09-050315 с Изменениями №3.
  350. Письмо ФАС от 22.12.2021 № ТН/109573/21 "О формировании документации на закупку лекарственных препаратов с МНН “Этанерцепт.”
  351. Bergman M, Patel P, Chen N, et al. Evaluation of Adherence and Persistence Differences Between Adalimumab Citrate-Free and Citrate Formulations for Patients with Immune-Mediated Diseases in the United States. Rheumatol Ther. 2021;8:109–18. doi: 10.1007/s40744-020-00256-x
  352. Yue X, Huang B, Hincapie AL, et al. Comparative effectiveness and persistence of TNFi and non-TNFi in juvenile idiopathic arthritis: a large paediatric rheumatology centre in the USA. Rheumatology. 2021;60:4063–73. doi: 10.1093/rheumatology/keaa877
  353. Галстян Л.А., Жолобова Е.С., Сучкова Д.В., Чебышева С.Н., Мелешкина А.В. Опыт эффективного долговременного применения адалимумаба в лечении пациента с ранним дебютом ювенильного идиопатического артрита и увеита // Педиатрия. Consilium Medicum. - 2020. - №2. - C. 67-71. doi: 10.26442/26586630.2020.2.200233
  354. Fernandez JM, Madsen S, Krase JM, et al. Classification and mitigation of negative injection experiences with biologic medications. Dermatol Ther. 2020;33:e13240. doi: 10.1111/dth.13240
  355. Houlton S. Benefits and drawbacks of moving to biosimilar medicines. Prescriber. 2019;30:13–5. doi: 10.1002/psb.1773
  356. Ruperto N, Brunner HI, Synoverska O, et al. Tofacitinib in juvenile idiopathic arthritis: a double-blind, placebo-controlled, withdrawal phase 3 randomised trial. The Lancet. 2021;398:1984–96. doi: 10.1016/S0140-6736(21)01255-1
  357. Huang Z, Lee PY, Yao X, et al. Tofacitinib Treatment of Refractory Systemic Juvenile Idiopathic Arthritis. Pediatrics. 2019;143:e20182845. doi: 10.1542/peds.2018-2845
  358. Алексеева Е.И., Крехова Е.А., Криулин И.А., Криулина Т.Ю., Дворяковская Т.М., Исаева К.Б., Чистякова Е.Г., Чомахидзе А.М., Ломакина О.Л., Фетисова А.Н., Чибисова К.В., Цулукия И.Т., Шингарова М.Ш., Ботова М.С., Кондратьева Н.М., Кокина М.Ю., Румянцев М.А. Опыт применения ингибитора янус-киназ упадацитиниба у детей с ревматическими болезнями. Вопросы практической педиатрии. 2024; 19(2): 59–79. DOI: 10.20953/1817-7646-2024-2-59-79.
  359. Nishimura K, Ishikawa T, Okamoto N, et al. Efficacy and safety of abatacept for systemic juvenile idiopathic arthritis: A systematic review. Mod Rheumatol. 2024;roae046. doi: 10.1093/mr/roae046
  360. Ruperto N, Lovell DJ, Quartier P, et al. Long‐term safety and efficacy of abatacept in children with juvenile idiopathic arthritis. Arthritis Rheum. 2010;62:1792–802. doi: 10.1002/art.27431
  361. Kuemmerle-Deschner J. Abatacept in difficult-to-treat juvenile idiopathic arthritis. Biol Targets Ther. 2009;865. doi: 10.2147/BTT.S3355
  362. Lim LSH, Lokku A, Pullenayegum E, et al. Probability of Response in the First Sixteen Weeks After Starting Biologics: An Analysis of Juvenile Idiopathic Arthritis Biologics Trials. Arthritis Care Res. 2023;acr.25003. doi: 10.1002/acr.25003
  363. Баранов АА, Алексеева ЕИ, editors. Ревматические болезни у детей. Москва: : ПедиатрЪ 2016.
  364. Henter J-I. Treatment of hemophagocytic lymphohistiocytosis with HLH-94 immunochemotherapy and bone marrow transplantation. Blood. 2002;100:2367–73. doi: 10.1182/blood-2002-01-0172
  365. Stephan JL. Reactive haemophagocytic syndrome in children with inflammatory disorders. A retrospective study of 24 patients. Rheumatology. 2001;40:1285–92. doi: 10.1093/rheumatology/40.11.1285
  366. I.A.Kriulin IAK, Kriulin IA, National Medical Research Center for Children’s Health, Moscow, Russian Federation, et al. Hemophagocytic lymphohistiocytosis: mechanisms of development, clinical manifestations, and treatments. Vopr Prakt Pediatr. 2021;16:94–102. doi: 10.20953/1817-7646-2021-6-94-102
  367. Zhang H, Yang S-W, Fu Y-C, et al. Cytokine storm and targeted therapy in hemophagocytic lymphohistiocytosis. Immunol Res. 2022;70:566–77. doi: 10.1007/s12026-022-09285-w
  368. Криулин И.А., Алексеева Е.И., Шилькрот И.Ю., Дворяковская Т.М. Лечение вторичного гемофагоцитарного синдрома у пациентов с системным ювенильным идиопатическим артритом. Результаты когортного ретроспективного исследования. Вопросы практической педиатрии. 2022; 17(5): 7–19. DOI: 10.20953/1817-7646-2022-5-7-19.
  369. Pelewicz K, Miśkiewicz P. Glucocorticoid Withdrawal—An Overview on When and How to Diagnose Adrenal Insufficiency in Clinical Practice. Diagnostics. 2021;11:728. doi: 10.3390/diagnostics11040728
  370. Alves C, Robazzi TCV, Mendonça M. Withdrawal from glucocorticosteroid therapy: clinical practice recommendations. J Pediatr (Rio J). 2008;84:192–202. doi: 10.2223/JPED.1773
  371. Кузьмина Н. И., Шох Б. П., Никишина И. П. Современный взгляд на системную глюкокортикостероидную терапию при ювенильном ревматоидном артрите //Научно-практическая ревматология. – 2000. – №. 2. – С. 56-62.
  372. Mouy R, Stephan J-L, Pillet P, et al. Efficacy of cyclosporine A in the treatment of macrophage activation syndrome in juvenile arthritis: Report of five cases. J Pediatr. 1996;129:750–4. doi: 10.1016/S0022-3476(96)70160-9
  373. Georgiadou S, Gatselis NK, Stefos A, et al. Efficient management of secondary haemophagocytic lymphohistiocytosis with intravenous steroids and γ-immunoglobulin infusions. World J Clin Cases. 2019;7:3394–406. doi: 10.12998/wjcc.v7.i21.3394
  374. Sen E. S., Clarke S. L. N., Ramanan A. V. Macrophage activation syndrome //The Indian Journal of Pediatrics. – 2016. – Т. 83. – №. 3. – С. 248-253.
  375. Papa R, Natoli V, Caorsi R, et al. Successful treatment of refractory hyperferritinemic syndromes with canakinumab: a report of two cases. Pediatr Rheumatol. 2020;18:56. doi: 10.1186/s12969-020-00450-9
  376. Bhat CS, Shetty R, Ramesh D, et al. Anakinra in Refractory Multisystem Inflammatory Syndrome in Children (MIS-C). Indian Pediatr. 2021;58:994–6. doi: 10.1007/s13312-021-2340-1
  377. Kostik MM, Isupova EA, Belozerov K, et al. Standard and increased canakinumab dosing to quiet macrophage activation syndrome in children with systemic juvenile idiopathic arthritis. Front Pediatr. 2022;10:894846. doi: 10.3389/fped.2022.894846
  378. Phadke O, Rouster-Stevens K, Giannopoulos H, et al. Intravenous administration of anakinra in children with macrophage activation syndrome. Pediatr Rheumatol. 2021;19:98. doi: 10.1186/s12969-021-00585-3
  379. Eloseily EM, Weiser P, Crayne CB, et al. Benefit of Anakinra in Treating Pediatric Secondary Hemophagocytic Lymphohistiocytosis. Arthritis Rheumatol. 2020;72:326–34. doi: 10.1002/art.41103
  380. Pal P, Bathia J, Giri PP, et al. Macrophage activation syndrome in pediatrics: 10 years data from an Indian center. Int J Rheum Dis. 2020;23:1412–6. doi: 10.1111/1756-185X.13915
  381. Wei A, Ma H, Li Z, et al. Short-term effectiveness of ruxolitinib in the treatment of recurrent or refractory hemophagocytic lymphohistiocytosis in children. Int J Hematol. 2020;112:568–76. doi: 10.1007/s12185-020-02936-4
  382. Kostik MM, Raupov RK, Suspitsin EN, et al. The Safety and Efficacy of Tofacitinib in 24 Cases of Pediatric Rheumatic Diseases: Single Centre Experience. Front Pediatr. 2022;10:820586. doi: 10.3389/fped.2022.820586
  383. Gómez Conde Santa Yarelis, Carrión Mendoza Reynaldo, del Toro Ravelo Laydenis María, Chia Proenza Daniel. Síndrome de activación de macrofágica como complicación de la artritis idiopática juvenil sistémica. Rev Cuba Reumatol [Internet]. 2021 Ago [citado 2022 Ago 02] ; 23( 2 ): e209. Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S1817-59962021000200011&lng=es. Epub 01-Ago-2021.
  384. Rovin BH, Adler SG, Barratt J, et al. KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases. Kidney Int. 2021;100:S1–276. doi: 10.1016/j.kint.2021.05.021
  385. Alekseeva E, Denisova R, Valieva S, et al. PReS-FINAL-2041: Macrophage activation syndrome in the children with systemic juvenile idiopathic arthritis during the course of tocilizumab. Pediatr Rheumatol. 2013;11:P54, 1546-0096-11-S2-P54. doi: 10.1186/1546-0096-11-S2-P54
  386. Rao S, Abzug MJ, Carosone-Link P, et al. Intravenous Acyclovir and Renal Dysfunction in Children: A Matched Case Control Study. J Pediatr. 2015;166:1462-1468.e4. doi: 10.1016/j.jpeds.2015.01.023
  387. Kimberlin DW. Acyclovir Dosing in the Neonatal Period and Beyond. J Pediatr Infect Dis Soc. 2013;2:179–82. doi: 10.1093/jpids/pis138
  388. Widasmara D, Firdausiya F. Disseminated Herpes Zoster on a Child with Systemic Lupus Erythematosus and Lupus Nephritis. Infect Drug Resist. 2021;Volume 14:2777–85. doi: 10.2147/IDR.S314220
  389. Balfour HH, McMonigal KA, Bean B. Acyclovir therapy of varicella-zoster virus infections in immunocompromised patients. J Antimicrob Chemother. 1983;12:169–79. doi: 10.1093/jac/12.suppl_B.169
  390. Whitley RJ. Herpes simplex virus in children. Curr Treat Options Neurol. 2002;4:231–7. doi: 10.1007/s11940-002-0040-2
  391. Antiviral Drugs in Children and Adolescents. Pediatr Infect Dis. 2020;1:123–8. doi: 10.5005/jp-journals-10081-1221
  392. Adler SP, Marshall B. Cytomegalovirus Infections. ;11.
  393. Lin X, Wan Y, Liu Y. Efficacy of ganciclovir in the treatment of cytomegalovirus (CMV) infection in infants and its effect on inflammatory reaction and immune function. Am J Transl Res. 2023;15:6514–23.
  394. Shim GH. Treatment of congenital cytomegalovirus infection. Clin Exp Pediatr. 2023;66:384–94. doi: 10.3345/cep.2022.01032
  395. Zhang S, Zhu Y, Jin Y, et al. Difference between Acyclovir and Ganciclovir in the Treatment of Children with Epstein–Barr Virus-Associated Infectious Mononucleosis. Evid Based Complement Alternat Med. 2021;2021:1–6. doi: 10.1155/2021/8996934
  396. Chellapandian D, Das R, Zelley K, et al. Treatment of Epstein Barr virus-induced haemophagocytic lymphohistiocytosis with rituximab-containing chemo-immunotherapeutic regimens. Br J Haematol. 2013;162:376–82. doi: 10.1111/bjh.12386
  397. Shimizu M, Nakagishi Y, Inoue N, et al. Interleukin-18 for predicting the development of macrophage activation syndrome in systemic juvenile idiopathic arthritis. Clin Immunol. 2015;160:277–81. doi: 10.1016/j.clim.2015.06.005
  398. Andrews A, Hickling P. Thrombosis associated with antiphospholipid antibody in juvenile chronic arthritis. Lupus. 1997;6:556–7. doi: 10.1177/096120339700600616
  399. Thomas KN, Aggarwal A. Childhood rheumatic diseases: bites not only the joint, but also the heart. Clin Rheumatol. 2023;42:2703–15. doi: 10.1007/s10067-023-06621-9
  400. Carcillo JA, Shakoory B, Castillo L. Secondary Hemophagocytic Lymphohistiocytosis, Macrophage Activation Syndrome, and Hyperferritinemic Sepsis-Induced Multiple-Organ Dysfunction Syndrome in the Pediatric ICU. In: Mastropietro CW, Valentine KM, eds. Pediatric Critical Care. Cham: Springer International Publishing 2019:245–55.
  401. Алексеева Е., Валиева С., Бзарова Т., Семикина Е., Исаева К., Лисицин А., Денисова Р., Чистякова Е., Слепцова Т., Митенко Е. Эффективность и безопасность отечественного рекомбинантного человеческого гранулоцитарного колониестимулирующего фактора при нейтропениях, развивающихся на фоне анти-в клеточной и иммуносупрессивной терапии у больных ювенильным ревматоидным артритом. Вопросы современной педиатрии. 2010;9(4):94-100.
  402. Yilmaz D., Ritchey A. K. Severe neutropenia in children: a single institutional experience //Journal of Pediatric Hematology/Oncology. – 2007. – Т. 29. – №. 8. – С. 513-518.
  403. Jog NR, Young KA, Munroe ME, et al. Association of Epstein-Barr virus serological reactivation with transitioning to systemic lupus erythematosus in at-risk individuals. Ann Rheum Dis. 2019;78:1235–41. doi: 10.1136/annrheumdis-2019-215361
  404. Segel, G. B., & Halterman, J. S. (2008). Neutropenia in pediatric practice. Pediatrics in review, 29(1), 12.
  405. Demirkol D, Yildizdas D, Bayrakci B, et al. Hyperferritinemia in the critically ill child with secondary hemophagocytic lymphohistiocytosis/sepsis/multiple organ dysfunction syndrome/macrophage activation syndrome: what is the treatment? Crit Care. 2012;16:R52. doi: 10.1186/cc11256
  406. El-Nawawy A, El-Kinany H, Hamdy El-Sayed M, et al. Intravenous Polyclonal Immunoglobulin Administration to Sepsis Syndrome Patients: A Prospective Study in a Pediatric Intensive Care Unit. J Trop Pediatr. 2005;51:271–8. doi: 10.1093/tropej/fmi011
  407. Vassilopoulos A, McCormick W, Lakhani A. Update in Hyperferritinemic Syndromes: Recognition and Management - A Scoping Review. J Brown Hosp Med. 2022;1. doi: 10.56305/001c.37667
  408. Henter J-I, Horne A, Aricó M, et al. HLH-2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer. 2007;48:124–31. doi: 10.1002/pbc.21039
  409. Малахов О. А. и др. Эндопротезирование тазобедренного сустава у подростков, больных ювенильным ревматоидным артритом //Вестник травматологии и ортопедии им. НН Приорова. – 2012. – №. 1. – С. 48-52.
  410. Yamamoto EA, Jørgensen TN. Relationships Between Vitamin D, Gut Microbiome, and Systemic Autoimmunity. Front Immunol. 2020;10:3141. doi: 10.3389/fimmu.2019.03141
  411. Takken T, Van Brussel M, Engelbert RHH, et al. Exercise therapy in juvenile idiopathic arthritis. Cochrane Database Syst Rev. Published Online First: 23 April 2008. doi: 10.1002/14651858.CD005954.pub2
  412. Hsieh L-F, Mao H-F, Lu C-C, et al. Rheumatologic Rehabilitation. Braddom’s Physical Medicine and Rehabilitation. Elsevier 2021:606-626.e1.
  413. Luttosch F, Baerwald C. Rehabilitation in der Rheumatologie. Internist. 2010;51:1239–45. doi: 10.1007/s00108-010-2626-1
  414. Stucki G, Kroeling P. Physical therapy and rehabilitation in the management of rheumatic disorders. Best Pract Res Clin Rheumatol. 2000;14:751–71. doi: 10.1053/berh.2000.0111
  415. Kuntze G, Nesbitt C, Whittaker JL, et al. Exercise Therapy in Juvenile Idiopathic Arthritis: A Systematic Review and Meta-Analysis. Arch Phys Med Rehabil. 2018;99:178-193.e1. doi: 10.1016/j.apmr.2017.05.030
  416. Sarac DC, Bayraktar D, Ozer Kaya D, et al. The effects of inspiratory muscle training on cardiorespiratory functions in juvenile idiopathic arthritis: A randomized controlled trial. Pediatr Pulmonol. 2024;59:562–73. doi: 10.1002/ppul.26783
  417. Elnaggar RK, Elfakharany MS. Aqua-Plyometric Exercises-Induced Changes in Muscle Strength, Bone Mineral Properties, and Physical Fitness in Patients With Juvenile Idiopathic Arthritis: A 12-Week, Randomized Controlled Trial. Pediatr Exerc Sci. 2023;35:198–205. doi: 10.1123/pes.2022-0044
  418. Azab AR, Kamel FH, Basha MA, et al. Impact of Clinical Pilates Exercise on Pain, Cardiorespiratory Fitness, Functional Ability, and Quality of Life in Children with Polyarticular Juvenile Idiopathic Arthritis. Int J Environ Res Public Health. 2022;19:7793. doi: 10.3390/ijerph19137793
  419. Elnaggar RK, Mahmoud WS, Abdelbasset WK, et al. Low-energy laser therapy application on knee joints as an auxiliary treatment in patients with polyarticular juvenile idiopathic arthritis: a dual-arm randomized clinical trial. Lasers Med Sci. 2021;37:1737–46. doi: 10.1007/s10103-021-03427-6
  420. Elnaggar RK, Mahmoud WS, Moawd SA, et al. Impact of core stability exercises on bone mineralization and functional capacity in children with polyarticular juvenile idiopathic arthritis: a randomized clinical trial. Clin Rheumatol. 2021;40:245–53. doi: 10.1007/s10067-020-05219-9
  421. Tarakci E, Arman N, Tarakci D, et al. Leap Motion Controller–based training for upper extremity rehabilitation in children and adolescents with physical disabilities: A randomized controlled trial. J Hand Ther. 2020;33:220-228.e1. doi: 10.1016/j.jht.2019.03.012
  422. Eid MAM, Aly SM, El-Shamy SM. Effect of Electromyographic Biofeedback Training on Pain, Quadriceps Muscle Strength, and Functional Ability in Juvenile Rheumatoid Arthritis. Am J Phys Med Rehabil. 2016;95:921–30. doi: 10.1097/PHM.0000000000000524
  423. Elnaggar RK, Elshafey MA. Effects of Combined Resistive Underwater Exercises and Interferential Current Therapy in Patients with Juvenile Idiopathic Arthritis: A Randomized Controlled Trial. Am J Phys Med Rehabil. 2016;95:96–102. doi: 10.1097/PHM.0000000000000347
  424. Field T, Hernandez-Reif M, Seligmen S, et al. Juvenile Rheumatoid Arthritis: Benefits from Massage Theraphy. J Pediatr Psychol. 1997;22:607–17. doi: 10.1093/jpepsy/22.5.607
  425. on behalf of PRINTO Egypt, El Miedany Y, El Gaafary M, et al. Shared decision-making aid for juvenile idiopathic arthritis: moving from informative patient education to interactive critical thinking. Clin Rheumatol. 2019;38:3217–25. doi: 10.1007/s10067-019-04687-y
  426. Mulligan K, Hirani SP, Harris S, et al. The Effects of a Web-Based Tool for Parents of Children With Juvenile Idiopathic Arthritis: Randomized Controlled Trial. J Med Internet Res. 2022;24:e29787. doi: 10.2196/29787
  427. Pérez Ramírez N, Nahuelhual Cares P, San Martín Peñailillo P. Efectividad de la terapia Watsu en pacientes con artritis idiopática juvenil. Un ensayo clínico controlado paralelo, aleatorio y simple ciego. Rev Chil Pediatría. 2019;90:282. doi: 10.32641/rchped.v90i3.886
  428. Chausset A, Gominon A-L, Montmaneix N, et al. Why we need a process on breaking news of Juvenile Idiopathic Arthritis: a mixed methods study. Pediatr Rheumatol Online J. 2016;14:31. doi: 10.1186/s12969-016-0092-6
  429. Scott C, Chan M, Slamang W, et al. Juvenile arthritis management in less resourced countries (JAMLess): consensus recommendations from the Cradle of Humankind. Clin Rheumatol. 2019;38:563–75. doi: 10.1007/s10067-018-4304-y
  430. Jansen MHA, Rondaan C, Legger GE, et al. EULAR/PRES recommendations for vaccination of paediatric patients with autoimmune inflammatory rheumatic diseases: update 2021. Ann Rheum Dis. 2023;82:35–47. doi: 10.1136/annrheumdis-2022-222574
  431. Heijstek MW, Ott de Bruin LM, Bijl M, et al. EULAR recommendations for vaccination in paediatric patients with rheumatic diseases. Ann Rheum Dis. 2011;70:1704–12. doi: 10.1136/ard.2011.150193
  432. Кокина М.Ю., Фомина Д.С., Лебедкина М.C., Мутовина З.Ю., Жолобова Е.С., Курбанова С.Х., Наргизян А.К., Фетисова А.Н., Анджель А.Е., Дворяковская Т.М., Шилькрот И.Ю., Алексеева Е.И. Эффективность и безопасность применения двухкомпонентного препарата моноклональных антител к SARS-CoV-2 (тиксагевимаб + цилгавимаб) для доконтактной профилактики новой коронавирусной инфекции у иммунокомпрометированных пациентов детского возраста с ревматическими заболеваниями. Предварительные результаты первого в Российской Федерации проспективного наблюдательного когортного исследования. Вопросы практической педиатрии. 2023; 18(1): 16–26
  433. Alexeeva EI, Dvoryakovskaya TM, Denisova RV, et al. Immunization With a Pneumococcal Polysaccharide Vaccine in Children With Juvenile Idiopathic Arthritis Without Systemic Manifestations: a Prospective Study. Curr Pediatr. 2017;16:493–501. doi: 10.15690/vsp.v16i6.1822
  434. Mori S, Ueki Y, Akeda Y, et al. Pneumococcal polysaccharide vaccination in rheumatoid arthritis patients receiving tocilizumab therapy. Ann Rheum Dis. 2013;72:1362–6. doi: 10.1136/annrheumdis-2012-202658
  435. Alekseeva EI, Van’kova DD, Soloshenko MA, et al. Pneumococcal Vaccine in Patients with Systemic Juvenile Idiopathic Arthritis Receiving Biologic Therapy: International Practice Review. Curr Pediatr. 2019;18:101–8. doi: 10.15690/vsp.v18i2.2012
  436. Novelli, V., & Holzel, H. (1999). Safety and tolerability of fluconazole in children. Antimicrobial agents and chemotherapy, 43(8), 1955-1960.
  437. Garcia-Lloret M, McGhee S, Chatila TA. Immunoglobulin Replacement Therapy in Children. Immunol Allergy Clin North Am. 2008;28:833–49. doi: 10.1016/j.iac.2008.07.001
  438. Rodriguez MM, Wagner-Weiner L. Intravenous Immunoglobulin in Pediatric Rheumatology: When to Use It and What Is the Evidence. Pediatr Ann. 2017;46. doi: 10.3928/19382359-20161214-01
  439. Scientific Centre of Children’s Health, Moscow, Russian Federation, Alexeeva EI, Denisova RV, et al. Intravenous Immunoglobulin in Pediatric Rheumatology Practice. Curr Pediatr Vopr Sovrem Pediatr. 2015;14:219–23. doi: 10.15690/vsp.v14i2.1290
  440. Mulhearn B, Bruce IN. Indications for IVIG in rheumatic diseases. Rheumatology. 2015;54:383–91. doi: 10.1093/rheumatology/keu429
  441. Prasad AN, Chaudhary S. Intravenous immunoglobulin in pediatrics: A review. Med J Armed Forces India. 2014;70:277–80. doi: 10.1016/j.mjafi.2013.05.011
  442. Marco H, Smith RM, Jones RB, et al. The effect of rituximab therapy on immunoglobulin levels in patients with multisystem autoimmune disease. BMC Musculoskelet Disord. 2014;15:178. doi: 10.1186/1471-2474-15-178
  443. Barmettler S, Ong M-S, Farmer JR, et al. Association of Immunoglobulin Levels, Infectious Risk, and Mortality With Rituximab and Hypogammaglobulinemia. JAMA Netw Open. 2018;1:e184169. doi: 10.1001/jamanetworkopen.2018.4169
  444. Khojah AM, Miller ML, Klein-Gitelman MS, et al. Rituximab-associated Hypogammaglobulinemia in pediatric patients with autoimmune diseases. Pediatr Rheumatol. 2019;17:61. doi: 10.1186/s12969-019-0365-y
  445. Gurbanov A, Gün E, Botan E, et al. Intravenous Immunoglobulin Use in Pediatric Intensive Care: A Single-Center Experience. 2023.
  446. Тепаев РФ. Синдром диссеминированного внутрисосудистого свертывания у детей. Диагностика и лечение. Педиатрическая Фармакология 2010;7:27–31.
  447. Opoka-Winiarska V, Grywalska E, Sobiesiak A, et al. The Impact of Epstein-Barr Virus Infection on Juvenile Idiopathic Arthritis Activity and Patient’s Response to Treatment. J Clin Med. 2020;9:3453. doi: 10.3390/jcm9113453
  448. Consolaro A, Giancane G, Alongi A, et al. Phenotypic variability and disparities in treatment and outcomes of childhood arthritis throughout the world: an observational cohort study. Lancet Child Adolesc Health. 2019;3:255–63. doi: 10.1016/S2352-4642(19)30027-6
  449. Овсянкина Е.С, Губкина М.Ф., Панова Л.В., Юхименко Н.В. Методы скрининга туберкулезной инфекции у детей и их роль в формировании групп риска и диагностике заболевания. Российский педиатрический журнал. 2017; 20 (2): 108-115. DOI: http://dx.doi.org/10.18821/1560-9561-2017-20 (2): 108-115.
  450. Koç R, Sönmez HE, Çakan M, et al. Drug reactions in children with rheumatic diseases receiving parenteral therapies: 9 years’ experience of a tertiary pediatric rheumatology center. Rheumatol Int. 2020;40:771–6. doi: 10.1007/s00296-019-04498-z
  451. Foster HE, Minden K, Clemente D, et al. EULAR/PReS standards and recommendations for the transitional care of young people with juvenile-onset rheumatic diseases. Ann Rheum Dis. 2017;76:639–46. doi: 10.1136/annrheumdis-2016-210112
  452. Allen V, Longley N. Infections in immunosuppressed travellers with autoimmune inflammatory diseases—a narrative review and advice for clinical practice. Rheumatology. 2021;60:3969–76. doi: 10.1093/rheumatology/keab445
  453. Whyte LA, Al-Araji RA, McLoughlin LM. Guidelines for the management of acute gastroenteritis in children in Europe. Arch Dis Child - Educ Pract Ed. 2015;100:308–12. doi: 10.1136/archdischild-2014-307253
  454. Bockemühl J, Roggentin P. Enterale Yersiniosen. Klinische Bedeutung, Epidemiologie, Diagnostik und Prävention [Intestinal yersiniosis. Clinical importance, epidemiology, diagnosis, and prevention]. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2004 Jul;47(7):685-91
  455. Wiger K., Høiby E. A., Wathne K. O. Infections in immunosuppressed children //Tidsskrift for den Norske Laegeforening: Tidsskrift for Praktisk Medicin, ny Raekke. – 2005. – Т. 125. – №. 9. – С. 1168-1172.
  456. Acebo J. J. et al. Infections in Immunosuppressed Pediatric Patients //Pediatric Surgical Oncology. – Cham : Springer International Publishing, 2023. – С. 1-34.
  457. Society P. I. D. et al. Guidelines for the Prevention and Treatment of Opportunistic Infections in Children with and Exposed to HIV //ClinicalInfo. HIV. gov [Internet]. – US Department of Health and Human Services, 2023.
  458. Allen UD. Management of infections in the immunocompromised child: General principles. LymphoSign J. 2016;3:87–98. doi: 10.14785/lymphosign-2016-0007
  459. Patrick C. C. Clinical management of infections in immunocompromised infants and children //(No Title). – 2001.
  460. Kwiatkowska B, Filipowicz‑Sosnowska A. Reactive arthritis. Pol Arch Intern Med. 2009;119:60–6. doi: 10.20452/pamw.606
  461. Sierra D, Wood M, Kolli S, et al. Pediatric Gastritis, Gastropathy, and Peptic Ulcer Disease. Pediatr Rev. 2018;39:542–9. doi: 10.1542/pir.2017-0234
  462. What’s New Adult and Adolescent Opportunistic Infection. AIDSinfo. https://aidsinfo.nih.gov/guidelines/html/4/adult-and-adolescent-opportunistic-infection/392/whats-new (accessed 14 Apr 2020).
  463. Pneumonia in Immunocompromised Patients: Overview, Causes of Pneumonia, HIV/AIDS. Published Online First: 26 June 2021.https://emedicine.medscape.com/article/807846-overview#a11.. (accessed 10 Aug 2021).
  464. Douglas AP, Smibert OliviaC, Bajel A, et al. Consensus guidelines for the diagnosis and management of invasive aspergillosis, 2021. Intern Med J. 2021;51:143–76. doi: 10.1111/imj.15591
  465. Islam MdA, Khandker SS, Alam SS, et al. Vitamin D status in patients with systemic lupus erythematosus (SLE): A systematic review and meta-analysis. Autoimmun Rev. 2019;18:102392. doi: 10.1016/j.autrev.2019.102392
  466. Bachrach LK, Ward LM. Clinical Review: Bisphosphonate Use in Childhood Osteoporosis. J Clin Endocrinol Metab. 2009;94:400–9. doi: 10.1210/jc.2008-1531
  467. Kutilek S, Plasilova I, Langer J. Ibandronate in the treatment of pediatric osteoporosis. Bone Abstracts. Bioscientifica 2015.
  468. Денисова Р., Алексеева Е., Пинелис В., Баканов М., Валиева С., Бзарова Т., Исаева К., Морев С., Кузнецова Г. Эффективность и безопасность ибандроновой кислоты для внутривенного введения при тяжелом системном остеопорозе у больных ювенильным артритом. Вопросы современной педиатрии. 2011;10(6):83–88.
  469. Ansell BM, Chamberlain MA. 11 Children with chronic arthritis: the management of transition to adulthood. Baillières Clin Rheumatol. 1998;12:363–74. doi: 10.1016/S0950-3579(98)80023-X
  470. Nascimento Leite M, Kamper SJ, O’Connell NE, et al. Physical activity and education about physical activity for chronic musculoskeletal pain in children and adolescents. Cochrane Database Syst Rev. 2023;2023. doi: 10.1002/14651858.CD013527.pub2
  471. Puxeddu I, Giori L, Rocchi V, et al. Hypersensitivity reactions during treatment with infliximab, etanercept, and adalimumab. Ann Allergy Asthma Immunol. 2012;108:123–4. doi: 10.1016/j.anai.2011.11.004

Для продолжения работы требуется Registration
На предыдущую страницу

Предыдущая страница

Следующая страница

На следующую страницу
Список литературы
На предыдущую главу Предыдущая глава
оглавление
Следующая глава На следующую главу

Table of contents

Данный блок поддерживает скрол*